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Background: This project utilized opioid-misusing adults to investigate the association between 
type of opioid misuse and perceived readiness, financial, structural, and stigma-related barriers to 
accessing SUD treatment; identified classes of PSU and the association between patterns of PSU 
and perceived barriers, and evaluated effectiveness of an out-of-hospital opioid-treatment 
connection program. 
Methods: Respondents from 2015-2018 NSDUH included insured adults reporting past year 
opioid misuse. Multivariate logistic regression assessed relationship between type of opioid 
misuse and perceived barriers to SUD treatment. LCA identified patterns of PSU, and 
multivariate logistic regression assessed association between PSU classes and perceived barriers. 
EMS ePCRs for nonfatal OOD from February 1st 2016 – January 31st 2020 were utilized for 
SITSA and MITSA to evaluate association between implementation of an out-of-hospital opioid-
treatment connection program and monthly trend of nonfatal OOD in the county of 
implementation and a control county.  
Results: Of 6,095 individuals, 3.7% perceived at least one barrier. LCA identified: Heroin 
injectors with high PSU, PPR users with low PSU, and PPR users with high PSU.  Heroin 
injectors with high PSU faced significantly greater odds of perceiving readiness, structural, and 
stigma-related barriers compared to PPR users with low PSU. The county of implementation 
reported an immediate decrease in nonfatal OOD by 0.34% each month post-intervention, 
however there were no significant differences in pre- to post-intervention level or slope between 
counties. 
Conclusions: The findings of this study can be used to develop public-health interventions 




Chapter 1: Background 
1.1 Human and Economic Toll of the United States Opioid Epidemic  
In 2017, a total of 47,600 opioid-related fatalities occurred in the United States – 
approximately 130 Americans killed every day.1 The annual number of drug overdose deaths in 
the United States has nearly tripled since 1999; with opioids, both prescription (oxycodone, 
oxycontin) and illicit (heroin, fentanyl), accounting for more than half of the lives claimed during 
that time period.2 The mortality resulting from the opioid epidemic is responsible for destroying 
families, consuming public safety resources and burdening the U.S. healthcare system. In 
November of 2017 the White House Council of Economic Advisers reported the total economic 
cost of the opioid crisis at close to $504 billion,3 with more than a third of that total economic 
burden likely made up of costs from reduced productive hours due to misuse/dependence, and 
expenses to the U.S. healthcare system.4  
1.2 Opioid Addiction Treatment in the United States  
The abrupt cessation of opioids may lead to strong cravings or intense symptoms of 
opioid withdrawal, which may encourage an individual to seek out and use opioids.5 To break 
the cycle of abuse, there are a variety of therapies which can be used to treat Opioid Use 
Disorder (OUD), including pharmacotherapies, behavioral therapies, and a combination of both. 
These treatments take place in a variety of settings throughout in the US; overall the majority 
(91.3%) take place in outpatient programs, followed by residential programs (7%), and hospital 
inpatient program (1%).6  
Pharmacotherapies. Evidence suggests that treating opioid addiction with medication is 
far more effective at keeping individuals in treatment and opioid-abstinent than using non-
medication treatment.7 Three medications are currently approved by the U.S. Food and Drug 
Administration to treat OUD: opioid-agonists methadone and buprenorphine, and the opioid-
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antagonist naltrexone.8 While sometimes mistaken as “heroin/opioid substitutes”, the effects of 
these medications differ from those of heroin and other misused opioids.9 Whereas the rapid 
onset of heroin produces immediate euphoria followed by a crash, methadone and buprenorphine 
have gradual onsets of action and maintain stable levels within the brain, decreasing an 
individual’s craving for opioids without a euphoric high.9 In 2017, facilities with opioid 
treatment programs reported more than a half-million individuals participated in medication-
assisted opioid therapy, 73.9% received methadone, 21.7% buprenorphine, and 4.5% received 
Naltrexone.6  
Behavioral therapies. Behavioral therapies help engage people in treatment for substance 
use disorder (SUD), enabling them to modify their attitudes toward opioid use, and help them 
develop coping mechanisms to handle physical and environmental cues that may trigger intense 
cravings for opioids.9 Although maintenance on medication-assisted treatments alone has been 
effective at reducing overdose deaths,10 research has also shown that both methadone and 
buprenorphine maintenance are more effective when included with some type of behavioral 
therapy.9 This is likely why the American Society of Addiction Medicine recommends 
psychosocial treatment in conjunction with any pharmacological treatment for OUD.5  
Despite the increased availability of treatment over the past decade,11 most individuals 
with OUD report no use of OUD treatment.12 Additional steps need to be taken to identify and 
address the variety of financial, structural, and stigma-related barriers that prevent individuals 
from accessing the treatment they need. 
1.3 Barriers to Accessing Treatment for Substance Use Disorder  
The gap for treatment of SUD is massive, that is, among those who need treatment for a 
SUD, few receive it.9 Between 2016 and 2017, the National Survey on Drug Use and Health 
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(NSDUH) estimated 17,484 individuals needed but did not receive treatment for substance use in 
the past year.13  
Perceived Need of Treatment. This gap primarily exists due to the substantial number of 
individuals who do not perceive a need for treatment of their substance use.14,15 In a 2015 survey 
conducted by Ali et al., 97% of respondents with a SUD reported not feeling a need for treatment 
or counseling for their alcohol or substance use.15 This perception persists because individuals 
are not be ready to stop using alcohol or drugs,15 believe they can handle their addiction on their 
own,16,17 or are not prepared to stop using alcohol or drugs.15 Yet, even among the small group of 
individuals feeling a need for treatment, barriers to accessing treatment for SUD persist.  
Financial barriers. Financial barriers are commonly cited by individuals acknowledging 
a need for SUD treatment,10,18–20  21 with individuals not seeking help due to an inability to pay 
for treatment,10,18,20,22 most often due to a lack of insurance.20,22 One study estimated around 12 
million uninsured Americans had a diagnosable mental or SUD,23 and Wu et al. found that 
uninsured adults are disproportionately affected by OUD.12  
Structural barriers. These financial barriers are likely exacerbated by the wide variation 
in the types of treatment for SUD and treatment coverage available in each state,24 which 
contribute to a variety of structural/organizational barriers. Restrictions placed on medications 
used in treatment can lead to a shortage of providers available to provide treatment,10,25–27 further 
impeding access by creating long waiting periods.28 Limited availability of programs 
disproportionately affects individuals living in rural areas,18 as well as vulnerable populations in 
need of special treatment accommodations, such as individuals who are pregnant,29 or those with 
co-occurring psychiatric disorders30 or disabilities.31 
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Stigma-related barriers. Lastly, stigma-related barriers are often cited for deterring 
individuals from seeking treatment, stemming primarily from a general lack of understanding 
about treatment for SUDs.18,31–34  Some individuals report not seeking treatment due to a lack of 
community support,18,31 and due to the belief that using medication assisted treatment was 
equilivant to substituting one addiction for another.18,34 In other cases the treatment itself was an 
issue, as individuals reported not wanting to seek treatment due to stigmatization and judgement 
from clinicians and agency personnel.31,32  
In order to address these barriers and reduce the treatment gap, strategies must be 
implemented to increase access to treatment for SUD, such as: achieving insurance parity, 
reducing stigma, and raising awareness among both patients and clinicians about value of 
addiction treatment.9   
1.4 Addressing Barriers through the Patient Protection and Affordable Care Act  
The United States government attempted to address many of these barriers to health care 
access through the Patient Protection and Affordable Care Act (ACA). The ACA aimed to 
increase healthcare access in three different ways: i) by extending insurance coverage through 
Medicaid expansion and state health insurance exchanges, ii) by requiring coverage of the 
essential health benefits package, including SUD screening and treatment services under both the 
Medicaid expansion program and the health plans offered on the state healthcare exchanges, and 
iii) by extending the 2008 mental health parity and addiction equity act: requiring insurers to 
cover SUD treatment in a no more restrictive way than medical and surgical services.23,24  
Since full implementation of the ACA in 2014, significant strides to increase healthcare 
access have been made: 22 million Americans gained access to insurance, essentially decreasing 
the number of uninsured Americans by half, from 48.6 million in 2010 to 28.6 million in 2015,35 
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and decreasing the rate of uninsurance for nonelderly adults to 10.2%.36 Studies have shown that 
the provisions of the ACA have greatly expanded the ability of individuals with SUD to obtain 
and maintain coverage.23  
In 2014, 81.5% of the respondents to the NSDUH with serious mental health or SUD 
reported insurance, a significant increase from all pre-2014 time periods,37 and another study 
from Feder et al. reported the prevalence of uninsured individuals with heroin use disorder 
declined dramatically from 2010 to 2015, largely due to the increased prevalence of Medicaid 
coverage.21  
Many researchers have credited the expansion of Medicaid as the driving force for many 
of the improvements in uninsurance;24,36,38  21Medicaid insured 13 million Americans,35 
including 1.6 million with SUD who gained insurance coverage in the Medicaid expansion 
states.24 Medicaid also accounted for the vast majority of new coverage among individuals with 
SUD, with use of Medicaid as a source of payment for SUD treatment increasing from 19.6% in 
2011-2013 to 27% in 2014.38  
Implementation of the ACA was not only instrumental in increasing the number of 
insured individuals with SUD, it also led to the proliferation of facilities offering SUD treatment 
and decreased the restrictions, requiring SUD treatments to be offered on par with medical and 
surgical procedures.24 Across the US, coverage for addiction treatment generally improved from 
2013-2017; the proportion of state plans providing benefits for residential SUD treatment and 
access to OUD medications dramatically increased, and annual service limits on outpatient 





1.5 Enrollment in Substance Use Disorder Treatment following the ACA 
Despite increases in insurance coverage and OUD medication availability following 
implementation of the ACA, the treatment rates for alcohol and SUDs have remained unchanged, 
as studies have reported no significant differences in SUD treatment utilization even up to three 
years following ACA implementation.21,37,40 
One factor significantly impacting enrollment in SUD treatment is variation in the 
expansion of state Medicaid programs.41,42 ACA allowed states to expand Medicaid to 
individuals whose incomes were at or below 138% of the federal poverty level;41 however, a 
2012 decision of the United States Supreme Court enabled states to choose whether or not to 
expand Medicaid, resulting in 19 states choosing not to expand.41 In 2017 the rate of uninsurance 
in non-expansion states was 2.5 times higher than in the expansion states, as many low-income 
individuals who make too much money to qualify for Medicaid but not enough to be able to 
afford a plan on the health care exchange.36 Medicaid was meant to play an important role in 
providing access to OUD treatment, as the program currently covers 30% of the 2.2 million 
Americans with prescription OUD.7 Thus, one possible explanation for stagnant enrollment in 
SUD programs could be because individuals in need of SUD treatment remaining uninsured 
because they reside in a non-expansion state.  
While many studies have focused on the persisting treatment access barriers of uninsured 
individuals, few have investigated the barriers experienced by insured individuals. While 
individuals who are insured are less likely to experience financial barriers to accessing treatment, 
they may continue to experience structural, motivational, and stigma-related barriers to accessing 
SUD treatment.20 For example, insured individuals may face barriers to access due to a lack of 
treatment availability. A shortage of physicians able to provide SUD treatment limits treatment 
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availability, and more than 30 million people live in U.S. counties without a single prescriber of 
medications for addiction treatment.10 Although one study showed that the number of physicians 
able to prescribe buprenorphine dramatically increased between 2003-2012, the demand for 
treatment in 2012 continued to overwhelm the capacity of available programs, with the majority 
of states reporting a treatment gap of at least 3 patients per 1000 people, and an overall gap of 
nearly 1 million people nationally.11   
Access to treatment among the insured may also be limited by service restrictions 
imposed by an individual’s insurance, such as restrictions on OUD medications used in 
treatment.43,44 One study sampling 100 policies on health insurance marketplaces found that 
plans were less likely to cover buprenorphine and naltrexone,45 and reported that buprenorphine 
was more likely than methadone to be subject to prior authorization and restrictions.45 In 
addition, clinicians report low reimbursement rates for OUD medications as a significant barrier 
to implementing addiction services program,26 leading some clinicians to decline accepting 
insurance for addiction services at all.25 Among those insured, those who are likely impacted 
most by service restrictions are individuals with Medicaid, as the benefits available vary widely 
from state-to-state.39,43 One promising study by Andrews et al. reported that Medicaid benefits 
for addiction treatment generally improved between 2014 and 2017: the proportion of state plans 
providing benefits for residential treatment and OUD medications states increased and the 
proportion of services and medications subject to annual limits decreased.39 Yet this study also 
reported that 15 states continued to prohibit coverage for short-term residential treatment, and 
only half provided coverage for long-term treatment.39 Variation in the services reimbursed 
cause many Medicaid recipients difficulty locating treatment facilities,22 especially facilities 
offering medications for addiction treatment.43 Alas, even when individuals with Medicaid find a 
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facility they may not be prioritized as patients or receive treatment equal to that received by 
individuals with private insurance, due to the lower fees reimbursement paid by Medicaid.35  
1.6 Shortcomings of Strategies Currently Addressing the Opioid Epidemic 
In addition to implementing the ACA, the United States has launched and promoted a 
variety of public health initiatives aimed at preventing opioid-related morbidity and mortality. 
Table 1.1 summarizes these strategies and their prevalence throughout the United States, and 
categorizes them as either “primary prevention” or “tertiary prevention” strategies, based on the 
three types of prevention strategies used by epidemiologists in response to disease epidemics.46  
Primary prevention aims to reduce the incidence of a disease or condition.46 Primary 
prevention strategies to address the opioid epidemic include prescription monitoring programs 
(PMP), which allow physicians to monitor the number of prescriptions a patient receives to deter 
overprescribing or “doctor shopping”,7,47,48 prescription limits which encourage physicians to 
limit the number of opioids in an initial opioid prescription,7 and prescription drug take-back 
programs, which allow individuals to dispose of unused opioid medications to prevent diversion 
or misuse.49 These initiatives aim to decrease the incidence of opioid misuse by limiting the 
number of prescribed opioids available for misuse.   
Tertiary prevention aims to prevent further disease through therapeutic and rehabilitative 
measures after a disease has been diagnosed.46 The majority of strategies addressing the opioid 
epidemic in the United States are tertiary prevention strategies, which aim to prevent future 
morbidity or morbidity associated with opioid misuse. Overdose fatalities could be further 
prevented by increasing public and layperson access to naloxone through overdose education 
and naloxone distribution programs50–53 and over-the-counter availability of naloxone,54,55 by 
ensuring overdose bystanders can call 911 without fear of arrest, as decreed in Good Samaritan 
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Legislation (GSL),55 or by allowing individuals to use pre-obtained drugs under the watch of 
trained staff in supervised drug consumption venues.56,57 In addition, the incidence of Human 
Immunodeficiency Virus (HIV) and Hepatitis C resulting from risky drug injection practices can 
be decreased through syringe-needle access programs.46   
Although one or more of these programs has been implemented in nearly every state in 
the nation,7 it is concerning that none of these initiatives employ secondary prevention, which 
emphasizes the screening of individuals for a health condition before it leads to serious 
complications.46 Upon screening an individual with OUD, a clinician could connect that 
individual with further addiction treatment, assisting them to bypass the various treatment access 
barriers discussed previously. While tertiary strategies are critical to decreasing the morbidity 
and mortality associated with the opioid epidemic, these strategies often end with detoxification, 
the first stage of addiction treatment, which by itself does little to change long-term drug use.9 To 
stop an addicted individual from compulsively seeking drugs and end the long-term cycle of 
abuse, drug treatment is a necessity,9 and identifying ways to connect individuals with addiction 
treatment is critical.  
1.7 Literature Summary 
Opioid treatment is the most effective way to overcome an opioid addiction, yet the 
number of individuals receiving treatment remains low. In the past, many of the barriers 
preventing an individual from seeking care were financial, due to lack of insurance and inability 
to pay out of pocket for treatment. The ACA was implemented in order to decrease financial 
barriers to accessing healthcare, and while the ACA greatly expanded access to insurance, 
enrollment into treatment for substance use disorder has remained unchanged. Although some 
studies have investigated the relationship between treatment enrollment and Medicaid expansion, 
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few have explored barriers to accessing treatment for SUD among insured individuals, and fewer 
still have focused on barriers to accessing OUD treatment. Additionally, although treatment 
initiatives in the United States have been effective in reducing the harm associated with opioid-
use, very few initiatives have focused on promoting the screening of OUD and connecting 
individuals with OUD to the addiction treatment they require.   
The aim of this dissertation was to address these research gaps by a) further investigating 
how sociodemographic and substance use characteristics are associated with barriers to accessing 
treatment for SUD, and b) evaluate the effectiveness of an out-of-hospital opioid treatment 
connection program on the number of nonfatal opioid overdoses. 
This dissertation pursued these study objectives through the investigation of three aims:  
1. Investigate the association between type of opioid misuse and perceived readiness, 
financial, structural, and stigma-related barriers to accessing treatment for substance 
use disorder among insured adults reporting past year opioid misuse.  
2. Identify patterns of past year polysubstance use among a nationally representative sample 
of opioid-misusing adults in the U.S. and evaluate the association between class of 
polysubstance use and perceived readiness, financial, structural, and stigma-related 
barriers to accessing treatment for SUD. 
3. Evaluate the impact of an out-of-hospital opioid treatment connection program on the 
number of nonfatal opioid overdoses 24-months post intervention. 
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Chapter 2. The association between type of opioid misuse and perceived barriers to 
accessing addiction treatment among insured opioid-misusing individuals 
 
Abstract 
Background: Little is known about the relationship between type of opioid misuse and access to 
treatment for substance use disorders. We investigated the association between type of opioid 
misuse and perceived readiness, financial, structural, and stigma-related barriers to accessing 
treatment for substance use disorder (SUD) among insured individuals reporting past year opioid 
misuse.  
Methods: Participants from the 2015-2018 National Survey on Drug Use and Health included 
insured individuals reporting past year misuse of prescription pain relievers (PPR), heroin (HO), 
or both (H+PPR). Chi-square analyses determined the association between participant’s 
predisposing, enabling, and need characteristics and type of opioid misuse. Multivariate logistic 
regression assessed the relationship between type of opioid misuse and all four perceived barriers 
to accessing treatment for SUD.  
Results: Of the 6,095 individuals reporting past year opioid misuse, 244 (3.7%) perceived at 
least one barrier to accessing treatment for SUD. Whereas HO users most often perceived 
financial (50.5%) and stigma-related (39.8%) barriers, readiness (45.5%, 50.9%) and structural 
(41.2%, 44.9%) barriers were most cited by those using PPR or H+PPR. Misuse of H+PPR and 
HO (vs. PPR only) significantly increased the odds of perceiving readiness (OR=2.80, 
95%CI=1.08-7.27), structural (OR=3.27, 95%CI=1.26-8.46), and stigma-related (OR=3.98, 
95%CI=1.42-11.21) barriers. Severe mental health symptoms and increased number of SUD also 
significantly increased the odds of perceiving all four barriers.  
Conclusions: Type of opioid misuse, mental health severity, and number of SUD are 
significantly associated with perceived barriers to accessing treatment for SUD. Targeted 
strategies that address individual-level factors (e.g., severe mental health problems, multiple 
SUD, type of opioid misuse) alongside population-level changes that increase availability of 






  Treatment of Opioid Use Disorder (OUD) is the most effective way to treat opioid-
related addiction and reduce the burden of this substance on the American health care system. 
Failure to enroll more individuals with OUDs into treatment has been costly to the U.S. 
healthcare system. In 2017 alone, a total of 47,600 opioid-related fatalities occurred in the United 
States. Further, the U.S. Council of Economic Advisors estimated the total economic cost of the 
opioid crisis in 2015 to be $504 billion.3  
The 2010 implementation of the Patient Protection and Affordable Care Act (ACA) 
extended private and public insurance coverage to millions of Americans. It also included 
screening and treatment services for substance use disorders (SUD) as essential benefits in health 
insurance plans, and required insurers to cover behavioral health services, including SUD 
treatment.23,58 Following implementation of the ACA, there were improvements in insurance 
rates among opioid-misusing individuals and increased availability of SUD treatment 
services.39,59,60 40 However, to date, there have been no significant differences in SUD treatment 
utilization even up to three years following implementation of the ACA.21,37,40 
It is likely that the ACA did not fully address four main barriers that reduce the likelihood 
of seeking SUD treatment, including: motivational (not yet ready to quit substance use or believe 
they can handle the addition on their own),17 financial (lack insurance or cannot afford 
treatment),22 structural (medication restrictions, long waiting periods, lack of availability, 
transportation),61–64 and stigma-related barriers (lack of community/family support, judgement 
from clinicians and healthcare providers)65–67.  
The recent shift in the type of opioid misuse from prescription opioids to heroin and 
synthetic opioids represents a structural barrier not fully addressed by the ACA and may have 
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contributed to an increase in opioid use rather than encouraging accessing opioid treatment.68,69 
The mortality rate due to synthetic opioids increased by 45.2% between 2016-2017. In contrast, 
prescription-opioid mortalities plateaued during this same timeframe.1 This is likely due to the 
influx of synthetic opioids such as fentanyl,70 which made heroin and synthetic opioids a more 
accessible alternative to prescription opioids.71 The shift in the type of opioid misuse had swift 
implications for the planning of harm reduction and SUD treatment initiatives.  
Overall enrollment in SUD treatment programs remains low among opioid-misusing 
individuals, despite continued efforts to expand insurance coverage and access to SUD treatment. 
While there has been a great deal of research on the barriers to accessing SUD treatment, to date 
no study has investigated the barriers perceived by individuals who have insurance. In addition, 
the national shift in type of opioid misuse over the past decade could impact how opioid-
misusing individuals perceive the accessibility of SUD treatment. No study has investigated the 
relationship between the type of opioid misuse and perceived barriers to accessing treatment for 
SUD. This study aimed to gain a better understanding of the relationship between type of opioid 
misuse and perceived barriers to accessing SUD treatment among insured adults in the United 
States. Therefore, the objective of this study was to investigate the association between type of 
opioid misuse and perceived barriers to accessing SUD treatment. 
 2.2 Methods  
2.2.1 Data Source and Population 
This study analyzed data from the 2015-2017 publicly available files of the National 
Survey on Drug Use and Health (NSDUH). The NSDUH is administered to the non-
institutionalized civilian population aged 12 and older,72 collecting detailed information on the 
use of alcohol, illicit drugs, mental illness, SUDs, utilization of behavioral health treatments, and 
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treatment barriers for behavioral health conditions and treatments.73 The NSDUH uses a 
stratified multistage area probability sample designed to represent each of the 50 states and the 
District of Columbia.72 The methodological process for the NSDUH aims at increasing the 
accuracy of self-reports, through the use of computer-assisted personal interviewing, audio 
computer-assisted self-interviewing, and assurances that individual responses will remain 
confidential.72 Data from 2015-2017 was chosen to represent the survey years when the ACA 
was fully implemented throughout the United States. Most provisions of the ACA were 
implemented by October of 2014, however there remained state-by-state variation for the 
implementation of others.74 For example, although the ACA called for states to expand Medicaid 
to individuals whose incomes were at or below 138% of the Federal poverty line,42,75 19 states 
initially declined to do so. Thus, data from 2015 and beyond was chosen to give the most 
accurate representation of perceived barriers to treatment that continue to persist after 
implementation of the ACA. 
The study population was made up of all individuals who reported past year misuse of 
prescription pain relievers (PPR), heroin (HO), or both heroin and PPR (H+PPR). The 
population included insured individuals between the ages of 18-64, to focus on the perceived 
barriers of individuals most likely to have obtained insurance as a result of the ACA.  
2.2.2 Outcome Variables 
The dependent variables in this study were four binary indicators (yes/no) for perceiving 
a readiness, financial, structural, or stigma-related barrier to accessing initial or additional 
treatment for SUD within the past 12 months. Membership in each barrier category was assigned 
from 11 responses to the question “Which of these statements explain why you did not get the 
treatment or counseling you needed for your use of  [substance]?”.72 Responses used to assign 
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barrier categories were similar to those used in previous studies, 21,37,73 these barriers are 
described in detail in Supplemental Table 2.1. Participants who responded yes to at least one of 
the responses assigned to a barrier were categorized as having perceived that barrier in the past 
12 months.  
2.2.3 Independent Variable 
Type of opioid misuse was assigned to all respondents who reported “time since last used 
heroin” or “most recent pain reliever misuse” during the last 12 months and included three 
categories: individuals who reported use of heroin only (HO, N=127), individuals who only 
reported misuse of prescription pain relievers (PPR, N=5,580), and individuals who reported 
misuse of both heroin and prescription pain relievers (H+PPR, N=388). 
2.2.4 Covariates  
The theoretical framework for this study was based on Ronald Anderson’s Behavioral 
Model of Health Services Use.76,77 This model theorizes that an individual’s use of healthcare 
services is a function of: the predisposition of the individual to use the services, an individual’s 
ability to secure services; and the individual’s need for such services.76 Covariates chosen to 
represent the predisposing, enabling, and need factors that make up Anderson’s model were 
selected based on previous literature.12,78,79 Predisposing characteristics include “biological 
imperatives” and social factors that represent family relationships and status in society.78 
Predisposing characteristics included in the current study were age in years (18-25/26-34/35-
49/50-64), sex (male, female), race/ethnicity (Non-Hispanic White/Non-Hispanic Black or 
African American/Non-Hispanic Asian/Hispanic/ other (including: Non-Hispanic native 
American or AK native, Non-Hispanic native HI or other pacific islander, and non-Hispanic 
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more than one race)), sexual identity (heterosexual/ lesbian, gay, or bisexual), and education 
level (less high school or high school grad/some college, associates, or college graduate).  
Enabling factors reflect financial and organizational factors that may enable service 
utilization.78 These included: total family income (≤ $20,000/ >$20,000), urbanicity (large 
metro/small metro/non-metro), insurance type (Medicaid/private/other (e.g., TRICARE, 
CHAMPUS, CHAMPVA, VA, military, Medicare, or “covered by insurance-type other”)), and 
survey year (2015/2016/2017).  
The need factors embody the perceived need for health services and the evaluated need 
(as diagnosed by a clinician). These included severe psychological distress as indicated by past 
year psychological distress measured by the K6 scale (yes (≥13)/no(<13)), self-reported health 
(excellent, very good, good/fair or poor), past year injection drug use (IDU) (yes/no), and 
additional SUD. The K6 scale is a measure of how often a respondent experienced symptoms of 
psychological distress (e.g., nervous, hopeless, restless, depressed, worthless, or run-down) 
during the past 12 months.72 Those with a score of 13 or greater were classified as having severe 
psychological distress in the past 12 months. 
Additional SUD was the total sum of all of SUD reported by the individual. For example, 
if an individual reported alcohol use disorder and cocaine use disorder, his/her number of 
additional SUD would be 2. All SUD were logically assigned based on whether the respondent 
met the criteria as defined in the fourth edition of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV).72  
2.2.5 Ethical Considerations 
Any analysis of publicly available secondary data, where information is recorded by the 
investigator in a manner that subjects cannot be identified (either directly or through identifiers) 
18 
 
is considered exempt by the Virginia Commonwealth University School of Medicine 
Institutional Review Board.80  
2.2.6 Analytic Strategy  
All data analyses were performed using SAS 9.4 (SAS Institute Inc, NC). Analyses 
accounted for the complex survey design of the NSDUH, and pooling of data for three years was 
accounted for by dividing the weight from 2017 data by three.72 Pearson Chi-square analyses 
were calculated to evaluate the association between predisposing, enabling, and need 
characteristics by type of opioid misuse. Bivariate logistic regression analyses were performed to 
assess the unadjusted association between the type of opioid misuse and all theoretical covariates 
with each of the perceived barriers to accessing SUD treatment (Supplemental Table 2.2). 
Multivariate logistic regression models were used to assess the association between type of 
opioid misuse and each perceived barrier, adjusting for all covariates (age, sex, race/ethnicity, 
sexual identity, education level, total family income, urbanicity, insurance type, survey year, 
self-reported health, severe psychological distress, past year IDU, and additional SUD).  
2.3 Results  
2.3.1 Study cohort 
Table 2.1 reports the characteristics of the study population by type of past year opioid 
misuse. The number of individuals from each survey year was evenly distributed, with 34.5%, 
34.3% and 31.3% in 2015, 2016, and 2017, respectively. The overall population was 
predominantly male (53.4%), white (69.6%), heterosexual (89.4%), and evenly distributed 
among the four age groups. The majority of the population had some college or graduated from 
college (62.6%), reported a total family income of less than $20,000 (78.4%), and lived in a large 
metropolitan community (56.9%). Nearly two-thirds (64.0%) reported having private insurance, 
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while just over a quarter reported having Medicaid (27.3%). Half reported having good/fair/poor 
health (49.8%), nearly a third reported severe psychological distress (31.7%) and 12.3% reported 
past year IDU. Although the majority of participants reported no additional SUD (67.7%), nearly 
a third (32.3%) reported at least 1 additional SUD.  
2.3.2 Sociodemographic characteristics by type of opioid misuse   
The majority of the 6,095 insured adults reporting past year opioid misuse were PPR 
users (91.6%), followed by H+PPR users (6.4%) and HO users (2.1%).  The proportion of males 
was significantly lower for PPR users (52.4%) compared to HO (67.4%) and H+PPR users 
(64.5%). Some college education was significantly more prevalent among PPR users (63.8%) 
compared to HO (44.2%) and H+PPR (51.1%) users, and the proportion earning less than 
$20,000 was significantly higher in HO (56.4%) compared to PPR (20.0%) and H+PPR (33.6%) 
users. In addition, two-thirds of PPR users (66.6%) were on private insurance, compared to only 
a third of HO (33.7%) and H+PPR users (35.0%), and the proportion of PPR users on Medicaid 
(24.8%) was nearly half that of HO (58.3%) and H+PPR (55.7%) users.  The proportion of HO 
reporting fair/poor health (71.9%) was significantly higher compared to PPR (48.9%) and 
H+PPR (56.1%) users, and fewer PPR users reported severe psychological distress (30.4%), in 
contrast to HO (42.5%) and H+PPR (49.1%) users. Further, past year IDU was significantly 
more prevalent among HO (61.4%) and H+PPR (70.2%) users compared to PPR users (7.6%), 
and the prevalence of 1 additional SUD (32.5%) or 3 additional SUDs (10.6%) were significantly 
higher in H+PPR users as compared to HO (17.7%, 2.7%) and PPR users (22.9%, 2.1%).  
The majority of the 244 respondents reporting at least one perceived barrier to accessing 
treatment for SUD were PPR users (70.4%), followed by H+PPR users (25%), and HO users 
(4.5%). Figure 2.1 illustrates the proportion of perceived barriers by type of opioid misuse 
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among individuals reporting at least one perceived barrier. Half (50.5%) of the HO users 
reported a financial barrier, followed by stigma-related barriers (39.8%), readiness barriers 
(30.9%), and less than a quarter (23.4%) perceived a structural barrier. In contrast, PPR users 
most often perceived readiness (45.5%) and structural (41.2%) barriers, followed by financial 
(31.6%) and stigma-related (29.5%) barriers. Similar to the PPR group, the most perceived 
barriers among H+PPR were readiness (50.9%) and structural (44.9%) barriers, while less than a 
third reported financial (31.2%) and stigma-related barriers (30.6%).  
2.3.4 Multivariable logistic regression of perceived barriers to treatment  
2.3.4a Type of opioid misuse and perceived treatment barriers 
Table 2.2 presents results from the multivariable logistic regression analysis of the 
adjusted association between type of opioid misuse and four perceived berries to assessing 
treatment. Type of opioid misuse was significantly associated with perceiving a readiness, 
structural, and stigma related barrier. Compared to individuals who only reported misuse of PPR, 
individuals reporting misuse of both H+PPR were at increased odds of perceiving a readiness 
(aOR=2.80, 95% CI=1.08-7.27), structural (aOR=3.27, 95% CI=1.26-8.46), or stigma-related 
(aOR=3.98, 95% CI=1.42-11.21) barrier to accessing treatment for SUD.  
3.3.4b Covariates of interest associated with perceived barriers 
Severe psychological distress. Individuals who reported severe psychological distress in 
the past year (as indicated by the K6 scale score ≥ 13) had an increased likelihood of perceiving 
all four barriers to accessing SUD treatment; reporting near triple the odds of perceiving a 
readiness (aOR=3.02, 95% CI=1.55-5.90), financial (aOR=2.45, 95% CI=1.05-5.70), structural 
(aOR=2.90, 95% CI=1.53-5.49), or stigma-related (aOR=2.90, 95% CI=1.42-5.92) barrier, 
compared to those not reporting severe psychological distress in the past year.  
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Additional SUD. Each additional SUD diagnoses increased the odds of perceiving a 
readiness (aOR=1.60, 95% CI=1.29-1.98), financial (aOR=1.25, 95% CI=1.08-1.44, or structural 
(aOR=1.34, 95% CI=1.11-1.62) barrier to accessing SUD treatment.  
2.4 Discussion  
Barriers to accessing treatment for SUD persist following nationwide implementation of 
the ACA in 2014. Among individuals reporting past year opioid misuse, 3.7% reported 
experiencing a barrier to accessing treatment for SUD. The findings of this study demonstrated 
that the association between perceiving barriers to accessing treatment and type of opioid misuse 
varied, and individuals reporting misuse of H+PPR during past year were more likely to perceive 
readiness, structural, and stigma-related barriers to care as compared to those reporting misuse of 
PPR only during the same period. Further, the results of this study identified two need 
characteristics (additional SUD and severe psychological distress) that increased the likelihood 
of perceiving each of the four barriers to accessing SUD treatment.   
2.4.1 Misuse of H+PPR increased odds of experiencing readiness, structural, and stigma-related 
barriers  
While past studies have focused on the association between type of opioid misuse and 
treatment outcomes,81–84 this is the first study to investigate the relationship between type of 
opioid misuse and perceived barriers to accessing treatment for SUD. Misuse of H+PPR 
significantly increased the odds of perceiving readiness, structural, and stigma-related barriers 
compared to misuse of PPR only.  
Readiness Barriers. Those misusing H+PPR had more than double the odds of perceiving 
a readiness barrier compared to those reporting PPR misuse alone. Among all substance users, 
perceived readiness to stop substance use is the most common reason for not engaging in 
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treatment for SUD.85 In Baltimore, over two-thirds (69.6%) of opioid overdose survivors 
reported not seeking treatment because they were not ready to stop substance use.85 This is 
consistent with how individuals with OUD view their “need” for treatment; between 2015-2016 
only 31.5% of individuals with OUD received treatment, and only 13.6% perceived the need for 
such treatment.86 One possible explanation for the increased likelihood of readiness barriers in 
H+PPR compared to PPR alone is the increased severity of OUD among the H+PPR group 
compared to the PPR group. Studies report only 3.6-4.2% of individuals who misuse PPR start to 
use heroin,87 suggesting that transitioning to heroin use appears to be part of the progression of 
addiction in a subgroup of nonmedical users of PPR.87 Further, individuals with HO or H+PPR 
addiction are more likely to engage in co-occurring substance use, and be diagnosed with SUD in 
addition to OUD.83,88 Thus, it might be possible that the stronger addiction severity in the small 
subgroup of H+PPR may influence their readiness to access SUD treatment. Very few studies 
have investigated how type of opioid misuse may influence readiness barriers to accessing SUD 
treatment. Future research should assess how type of substance use influences the reasons that 
opioid users are not ready for treatment, to improve efforts to motivate these individuals to 
engage in SUD treatment.  
Structural Barriers. Individuals in the H+PPR group were three times more likely to 
perceive a structural barrier compared to those with PPR misuse only. One potential explanation 
for the increased odds of perceiving structural barriers is inadequate coverage for services; as 
over half of the H+PPR group had Medicaid compared to the PPR group (55.7% vs. 24.8%). 
However, although Medicaid recipients in the current study had an increased likelihood of 
experiencing a structural barrier compared to those with private insurance, this relationship was 
not statistically significant. This is surprising given the findings of previous studies, which 
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reported that individuals with Medicaid were more likely to be turned away from care compared 
to those with employer-sponsored coverage,89 and that SUD treatment facilities were not 
adequately prepared for an influx of patients with Medicaid.60 However, the findings of the 
current study should also not be used to fully dismiss inadequate coverage of SUD services as a 
potential explanation, as the analysis could not account for the state-by-state differences in SUD 
service coverage for Medicaid recipients.  
In addition, it is also possible that the increased severity of addiction in the H+PPR group 
would require more intensive SUD treatment that is often unavailable due to insurance 
restrictions on SUD services. The American Society of Addiction Medicine report that patients 
who engaged in co-occurring substance use might need additional supervision to consider 
methadone or inpatient/residential SUD treatment for additional monitoring during withdrawal.90 
Yet even after the implementation of the ACA these treatment options present challenges. For 
example, methadone can only be legally prescribed to patients who are able to make daily visits 
to an opiate treatment program, which limits accessibility to individuals who work or live in rural 
areas far away from the treatment program.91 Further, these options may not be covered by 
insurance, as many states restrict coverage of methadone and residential services for individuals 
on Medicaid.60,92 The findings of the current study provide additional support for the findings of 
previous researchers, who have concluded that implementation of the ACA has not altered the 
tiered nature of health care access.89 State and local governments should work to decrease limits 
placed on SUD treatment, and increase the number of facilities accepting Medicaid.  
Stigma-related Barriers. Individuals in the H+PPR group had nearly four times the odds 
of perceiving a stigma-related barrier compared to those reporting PPR misuse. Among 
individuals with any type of SUD, 10-23% report stigma as a barrier to seeking SUD treatment,66 
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reporting stigmatization from healthcare providers,65,66,93,94 family and friends, and self-stigma 
(e.g., feelings of shame).66,93 Surprisingly, race/ethnicity and urbanicity, often reported as risk 
factors for stigmatization, were not significantly different among the groups.95 One explanation 
for the increased likelihood of H+PPR to perceive barriers due to stigma compared to the PPR 
group may be related to the disproportionately high number of individuals who inject drugs in 
the H+PPR group compared to the PPR group (70.2% vs. 7.6%). Individuals who inject drugs 
often report negative interactions with healthcare professionals,96,97 reporting that injecting 
carries a higher stigma than other methods of drug delivery like smoking or ingesting.98 Further, 
studies show that clinicians often admit to stigma specifically concerning individuals who inject 
drugs.99 Thus, the H+PPR group may feel more susceptible to privacy concerns while receiving 
treatment, and consequently may want to avoid a daily visit that might draw negative attention 
from others.95   
It is difficult to assess the consistency of these findings with those of previous literature, 
as no previous studies have explored the association between type of opioid misuse and 
perceived stigma.  
2.4.2: Covariates of interest associated with perceived barriers to accessing SUD treatment  
Additional SUD. Each additional diagnosis of SUD increased the odds of experiencing 
readiness, financial, and structural barriers. Between 77.2-93.3% of individuals with OUD report 
an additional SUD,100,101 and previous literature shows how detrimental additional SUDs can be 
on treatment outcomes, often increasing the risk of dropout.102–104 It is not surprising that those 
with additional SUD are more likely to perceive a readiness barrier, as individuals with 
additional SUD are less likely to seek out treatment or end current substance use compared to 
individuals using opioids alone. In addition, as facilities are recommended to provide opioid-
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misusing individuals with co-morbid SUD with an individualized approach, these findings may 
indicate a continued demand for programs to meet this need.   
Mental Health Severity. Mental health severity was the only characteristic that was 
significantly associated with the increased likelihood of perceiving all four barriers to accessing 
treatment for SUD. This is an important finding, as comorbid psychiatric disorders are highly 
prevalent, reported in 64.3-68.4% of individuals with OUD100,105 and 78-78.5% of individuals 
receiving treatment for OUD.103,106 These findings are supported by the results of previous 
studies which report that individuals on Medicaid are less likely to receive SUD treatment. In 
2014 a study of Medicaid clients with OUD found that those with severe mental disorders, such 
as schizophrenia and/or bipolar were far less likely to receive medicated assisted treatment 
compared to individuals without those diagnoses.107 These findings are also consistent with a 
previous analysis using the NSDUH data from 2008-2014, in which a high proportion of 
individuals with mild to serious mental illness and comorbid OUD reported not receiving needed 
SUD treatment; with over half reporting a perceived barrier due to affordability, and close to a 
third citing barriers due to stigma or lack of readiness.108 The consistency between the results of 
the current study and previous literature may imply that changes following the ACA have not 
completely addressed treatment access barriers specific to those with severe mental illness. 
Further research is needed to understand how to address these barriers to help individuals with 
comorbid mental illness successfully participate in SUD treatment.  
2.4.3 Strengths and Limitations 
The NSDUH is the nationally representative source of annual estimates of drug use and 
mental illness among civilian members of the noninstitutionalized population in the United 
States.109 This survey uses tools to assure privacy and confidentiality of all participant’s 
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responses, to increase the likelihood of honest reporting of illicit drug use and illegal activities. 
The response rate for each of the three years included here were relatively high, ranging between 
69.7- 67.1%.110–112 In addition, this study was strengthened by the use of the Behavioral Model 
of Health Services Use, making the findings easier to adapt to support the design of community-
based interventions that could address the disparities in accessing SUD treatment faced by the 
OUD community.  
 These findings are also subject to several limitations. This survey is cross-sectional and 
not longitudinal; inferences for individuals cannot be made over the three-year period and 
direction of effect and causality cannot be determined. Additionally, questions about the use of 
illegal substances may discourage participant’s candor, thus responses could be influenced by 
social desirability bias. Further, responses may be subject to recall bias, as many questions 
required participants to recall events taking place over the past 12 months. 
The current study did not account for additional factors associated with stigma related 
barriers to treatment, such as pregnancy, parenthood, marital status, and Human 
Immunodeficiency Virus status. 21,66 Future investigation into this relationship should consider 
inclusion of these factors to expand on the work of this analysis.  
Interpretation of these findings are limited to individuals with additional SUD, and 
should not be generalized to opioid-misusing individuals who may engage in the use of multiple 
substances but do not have an additional SUD. Additional information on these individual’s 
patterns of substance use may be beneficial to the development of interventions for increasing 
treatment access. Future research should more accurately capture patterns of co-occurring 
substance use in order to better understand the relationship between patterns of substance use and 
perceived barriers to accessing SUD treatment. 
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Finally, generalizability of these findings are limited to the civilian, noninstitutionalized 
population of the United States. Although this only excludes approximately 3% of the U.S. 
population,114 it likely excludes several subgroups considered to be at increased risk for OUD, 
including prisoners, military personnel, and the homeless. Additionally, the interview can only 
be conducted in English and Spanish, which excludes all non-English and Spanish speakers.114 
Exclusion of these groups may not only limits the generalizability of findings, but also result in 
the underestimation of the true prevalence of less commonly used drugs, including heroin.114 
2.5 Conclusions 
This study highlighted that different types of opioid misuse could be associated with 
perceived barriers to accessing treatment, and the association could be further impacted by 
severe psychological distress and additional SUD. The shift in opioid misuse from PPR to heroin 
and synthetic opioids has important implications for the development of effective treatment 
strategies for individuals with SUD.  Further work is needed to better understand how these 
specific treatment barriers might influence type of opioid misuse. 
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Chapter 3. The influence of patterns of polysubstance use on perceived barriers to 
accessing treatment for substance use disorder 
 
Abstract 
Background: Opioid users engaging in polysubstance use (PSU) are at increased risk of 
overdose and mortality, yet little is known about the relationship between PSU and barriers to 
accessing substance use disorder (SUD) treatment. This study investigates the association 
between PSU classes and perceived readiness, financial, structural, and stigma-related barriers to 
accessing SUD treatment.  
Methods: Data were included from the 2015-2017 National Survey on Drug Use and Health. 
Latent Class Analysis (LCA) determined patterns of PSU in 6,095 insured adults reporting past-
year misuse of prescription pain relievers (PPR), heroin, or both. Multivariate logistic regression 
assessed the relationship between PSU classes and perceived barriers to accessing SUD 
treatment, adjusted for age, sex, race, sexual identity, education, total family income, urbanicity, 
insurance, survey year, self-reported health, severe psychological distress, average daily cigarette 
use, and accounting for complex survey design.  
Results: LCA identified three patterns of past-year PSU: 1) Heroin injectors with high PSU 
(n=473, 7.8%), 2) PPR users with low PSU (n=4,000, 26.6%), and 3) PPR users with high PSU 
(n=1,622, 65.6%). Heroin injectors with high PSU faced significantly greater odds of perceiving 
readiness (aOR=3.11, 95%CI=1.43-6.77), structural (aOR=2.42, 95%CI=1.22-4.79), and stigma-
related (aOR=3.13, 95%CI=1.31-7.48) barriers to accessing SUD treatment compared to PPR 
users with low PSU.   
Conclusions: These findings highlight a subpopulation of opioid users at increased odds of 
perceiving readiness, structural, and stigma-related barriers to accessing SUD treatment. 
Targeted public health efforts are necessary to decrease perceived barriers to accessing treatment 






Polysubstance use (PSU) is often defined as the concurrent or simultaneous consumption 
of more than one substance over a specified period of time.115 Many studies consider the 
combined or subsequent use of both licit (alcohol, tobacco), and illicit (cocaine, 
methamphetamines, marijuana, sedatives, etc.) substances as PSU. PSU is increasingly being 
recognized as a problem by the public health community, due to increases in the number of 
multi-drug combination deaths. Jones et. al reported an increase in the rate of benzodiazepine 
involvement in opioid overdose deaths, from 18.0% in 2004 to 31.0% in 2011,116 and Kandel et 
al., reported an increase in deaths resulting from a combination of prescription opioids with at 
least one additional psychoactive substance (benzodiazepines, antidepressants, heroin, alcohol, 
and cocaine) from 44.3% in 2002-2003 to 57.9% in 2014-2015.117 In addition, PSU increases an 
individual’s risk of a variety of adverse health outcomes, including: psychopathology,118,119 
chronic health conditions,118 risk-taking behaviors,119 criminal activity,120,121 and nonfatal 
overdose.122–124 
3.1.1 PSU use among opioid-misusing individuals  
The increase in opioid-related fatalities over the past two decades may be partially 
explained by deaths resulting from the combination of opioid use and PSU.117 Prevalence of PSU 
among opioid-misusing individuals is fairly high. Approximately 53-89.6% of opioid-misusing 
populations report PSU.122,125–127 Opioid-misusing individuals most often report the co-use of 
tobacco,120,128 alcohol,129–133 cannabis,130,132,133 cocaine,122,127,131 benzodiazepines,130–132 and 
methamphetamines127. While the high prevalence of PSU among opioid users may be due to an 
increased likelihood of opioid use among individuals with substance use disorders (SUD) (e.g. 
alcoholism, etc.), it is most likely due to the use of certain substances (i.e., cocaine, 
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benzodiazepines, methamphetamines) to enhance opioid intoxication, or alleviate the symptoms 
of opioid withdrawl.134–136 
Opioid-misusing individuals with PSU are less responsive to treatment for SUD than 
individuals without PSU disorders.120,137 Many opioid-misusing individuals entering SUD 
treatment report co-occurring use of alcohol, marijuana, cocaine, and benzodiazepines,138,139 and 
75-86.0% of individuals entering opiate treatment report tobacco use.140–142 Individuals 
continuing PSU during SUD treatment are at increased risk of relapse143,144 and attrition.82,139,145–
147 Further, co-occurring PSU can significantly increase the likelihood of mortality during 
treatment; Ries et al. reported that the majority of deaths occurring during methadone treatments 
are attributed to polysubstance overdoses,128 and Lofwall et al. reported buprenorphine-related 
deaths most often occurred due to the concomitant use of central nervous system 
depressants.128,148  
Currently, the opioid-agonist methadone demonstrates the most comprehensive evidence 
of efficacy in individuals with co-occurring SUDs.149 Studies investigating outcomes of 
methadone administration report statistically significant decreases in PSU following 
treatment.150–152 In addition, in 2015 Ries et al. reported that individuals with Opioid Use 
Disorder (OUD) and PSU dependence could be effectively managed in an inpatient facility that 
offers 24-hour medical monitoring.128 Nevertheless, individuals engaged in PSU have the lowest 
likelihood of opioid treatment success. 
3.1.2 Barriers to accessing treatment for polysubstance users 
Compared to studies of opioid treatment outcomes, there are few that investigate the 
association between PSU and opioid treatment enrollment and detail the role of barriers to 
seeking such care. Previous studies suggest that individuals engaged in opioid use and PSU 
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actively seek treatment for emergency and behavioral health services125. For example, Calcaterra 
et. al. reported significantly higher incidence rate ratios for opioid users and individuals reporting 
multiple drug use accessing behavioral and emergent health care compared to those reporting no 
drug use125. Yet few studies detail how engagement and treatment seeking behaviors might differ 
between those using opioids and those engaging in PSU.  
Opioid users with PSU are likely to experience barriers to accessing opiate treatment 
programs. This could be due to lingering guidelines of past programs, where continued use of 
additional substances during opiate treatment programs was considered grounds for dismissal 
from treatment. Although the Federal Drug Administration advised against the removal of 
patients engaging in PSU from treatment in 2017, stating that the harm caused by untreated 
opioid addiction could outweigh the risks of serious side effects from PSU.153  
Despite this recommendation, individuals with PSU may still face structural barriers to 
accessing the most appropriate treatment for their needs. However, state and Federal control over 
these types of opioid treatment decrease their accessibility. Methadone remains the most 
restricted OUD medication in the US,154 which may pose structural barriers to individuals 
seeking treatment. Moreover, inpatient SUD programs are the least likely to be funded by private 
insurance and Medicaid, creating financial deterrents to seeking treatment. Although addressing 
these barriers is crucial to make SUD treatment available to opioid users, to date no study has 
examined the barriers to accessing opioid treatment faced by individuals engaging in PSU.  
3.1.3 Issues defining PSU   
 Examining treatment outcomes in the context of polysubstance or polydrug use is 
difficult, as it can involve a variety of licit and illicit substance configurations, making it 
challenging to identify salient categories.155 As there is currently no standardized way to account 
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for PSU, studies use a variation of definitions, such as “multiple drugs at the same time” ,156 or 
“summing the total number of substances used”,157 while other studies provided no explanation 
for how PSU was defined.144,158–160  Due to the variety of configurations for the types and 
frequency of substance use, it is not possible to directly observe “patterns” of polysubstance use, 
but these patterns may be determined through the observation of related variables.161 One method 
used to identify substance use patterns is latent class analysis (LCA),162 which can define a 
hidden or “latent” variable within which the manifest variables are locally independent.162 In 
other words, if “polysubstance use” can be defined as a latent variable, then the classes of 
polysubstance use are taken to represent latent types of the polysubstance use as defined by 
measures of substance use within the sampled population. Identification of the polysubstance use 
latent variable could enable a better understanding of the socio-demographic and clinical 
differences between substance—using subgroups, and how perceived barriers to accessing 
treatment for SUD may differ among these substance-using subgroups.163 
Previous studies have used LCA to identify patterns of substance use based on the 
substances used,115,120,132,155,164–169 or routes of substance administration.123,170–174 Previous LCA 
have examined the relationship between PSU classes and a variety of health-related outcomes, 
including: risky drug use behaviors,155,167,172 Human-immunodeficiency virus (HIV) risk 
behaviors,123,170,173 psychological distress,167 recent overdose,174 and mortality,165 however only 
two studies explored the differences in healthcare utilization and treatment.120,155 In 2018, 
Lorvick et al. reported that among women using ‘hard drugs’ – cocaine, methamphetamines, or 
heroin – the heavy polydrug class had significantly higher odds of unmet physical and mental 
healthcare needs.155 These findings highlight the importance of identifying barriers that may 
keep individuals with PSU from accessing care.  
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One large limitation of previous LCA characterizing patterns of PSU is a lack of 
generalizability, either due to the choice of population or limited inclusion of substances 
included in the LCA. Of the 8 previous LCA which reported patterns of PSU among opioid 
users,123,132,164,165,171,173,174 only 2 use a population from the United States.164,171 Yet the patterns 
of PSU among these populations are likely different to what would be observed in a nationwide 
population of opioid users. For instance, Kuramoto et al. performed an LCA using responses 
from participants reporting weekly use of heroin or cocaine in a large U.S. city,171 and Bobashev 
et al. recruited heroin-using individuals from a syringe exchange program in a large U.S. city.164  
Previous LCA are further limited in the information they provide due to variation in the 
substances chosen for inclusion in the LCA. Among the LCA in opioid-misusing populations, 
substances most often included were methamphetamines, marijuana, cocaine, and 
heroin.123,132,164,165,171,175 Only half (50.0%) included misuse of prescription pain relievers 
(PPR)/prescription opioids and alcohol.123,164,165,175 Very few studies included the use of 
benzodiazepines, barbiturates, crack, hallucinogens, ketamine, power cocaine, speedball, 
stimulants, tranquilizers, and inhalants.123,132,171,175 The aforementioned limitations of previous 
LCA highlight gaps which may limit accurate characterization of PSU patterns, and support the 
need for an additional LCA to characterize patterns of PSU in a nationwide sample of opioid-
misusing individuals. 
The lack of consensus of the definition of PSU among opioid users limits the 
generalizability of previous studies that identify the barriers to seeking opioid treatment. 
Additionally, although past research has indicated poorer treatment engagement among 
polysubstance users, no study has yet examined the relationship between patterns of substance 
use and barriers to accessing treatment for SUD among opioid-misusing individuals. The 
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objectives of this study were twofold: 1) identify patterns of past year PSU among a nationally 
representative sample of opioid-misusing adults in the U.S., and 2) evaluate the association 
between membership in PSU classes and perceived readiness, financial, structural, and stigma-
related barriers to accessing treatment for SUD.   
3.2 Methods 
3.2.1 Data Source and Study Design  
This study utilized data from the 2015-2017 National Survey on Drug Use and Health 
(NSDUH), a survey sponsored by the Substance Abuse and Mental Health Services 
Administration, within the U.S. Department of Health and Human Services.176 The survey is 
administered to the non-institutionalized civilian population aged 12 and older, collecting 
detailed information on the use of alcohol, illicit drugs, mental illness, SUDs, utilization of 
behavioral health treatments, and treatment barriers for behavioral health conditions and 
treatments.73  
The NSDUH uses a stratified multistage area probability sample designed to represent 
each of the 50 States and the District of Columbia. Each sampled individual was scheduled for a 
60-minute interview conducted in a private area of the home on a laptop provided by the field 
investigator. To increase cooperation and honest reporting about sensitive topics, the NSDUH 
employs methodological practices aimed at increasing the accuracy of self-reports, using a 
combination of computer-assisted personal interviewing and audio computer-assisted self-
interviewing, and by providing assurances that individual responses will remain confidential.177 





3.2.2 Study Population  
Similar to Chapter 2, this study used publicly available data from the NSDUH from 2015-2017, 
which represents the period after the Patient Protection and Affordable Care Act (ACA) was 
implemented throughout the U.S. Inclusion in this study was also limited to insured adults 
between the ages of 18-64, who reported past year use of heroin, past year misuse of PPR, or 
both.  
3.2.3 Measures  
Past year Substance Use. Indicator variables included in the LCA model were binary 
indicators for the past year use of 12 substances (based on the question “Most recent use of 
[substance]), and binary measures reporting past year injection of substances (based on the 
question: “Time since last used needle to inject [substance]?”).  
The substances assessed included: binge alcohol use, (defined as drinking 5 or more 
drinks on the same occasion for males and four or more drinks on the same occasion for 
females), crack, cocaine, hallucinogens (LSD, PCP, Ecstasy, DMT/AMT/Foxy, Ketamine, and 
Salvia), heroin, inhalants, methamphetamines, marijuana, PPR, sedatives, stimulants, and 
tranquilizers. Injection of four substances was also assessed, including: cocaine, heroin, 
methamphetamines, or “other” substances. 
Binge alcohol use was selected to distinguish between less harmful occasional alcohol 
use and more problematic binge drinking. As a recent study reported that the prevalence of 
opioid misuse increases with the frequency of binge drinking,179 it is reasonable to expect that 
binge drinking adults would be at greater risk for an overdose due to an interaction between 
alcohol and opioids.  
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All substances selected for inclusion in the current LCA were also included in previous 
studies for classifying subtypes of PSU. Surprisingly, of the 8 previous studies characterizing 
PSU in opioid-misusing populations, none included tobacco use as an indicator variable, despite 
the high prevalence of tobacco use among opioid users.128 This is likely because the high 
prevalence of tobacco use among opioid-users would not be a distinguishing factor between 
classes. To ensure comparison of our classes to classes of other studies, tobacco use was not 
included as an indicator variable in the LCA, but instead was accounted for in the final 
regression analyses.   
Use of PPR, stimulants, tranquilizers, and sedatives were only included if the respondent 
indicated past year misuse, defined as: Use of [medication] in a way the doctor did not direct, 
including: using it without a prescription, using it in greater amounts, more often, or longer, or 
using it in any other way a doctor did not direct.178 These categories are created by the NSDUH 
to represent a combination of prescriptions commonly misused. Further information on 
substances included in the prescription drug categories is available in Supplemental Table 3.1.  
 Sociodemographic Variables. Covariates were selected to match the model previously 
described in Chapter 2, and included;  sex (male/female), age (18-25/26-34/35-64), race/ethnicity 
(Non-Hispanic White/Non-Hispanic Black, African American/Non-Hispanic 
Asian/Hispanic/Other), sexual identity (heterosexual/lesbian, gay, or bisexual), education level 
(less high school or high school grad/some college, associates, or college graduate), total family 
income (≤ $20,000/ >$20,000), urbanicity (large metro/small metro/non-metro), type of health 
insurance (Medicaid/Private/ other (e.g., TRICARE, CHAMPUS, CHAMPVA, VA, military, 
Medicare, or “covered by insurance-type other”)), survey year (2015/2016/2017), severe 
psychological distress as indicated by the K6 scale (yes (≥13)/no(<13)), self-reported physical 
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health (excellent, very good, good/fair or poor), past year tobacco use (defined as any reported 
past year use of cigarettes, cigars, pipes, or smokeless tobacco), and average number of cigarettes 
used per week (≥1-1 per day/2 to 5 per day/6 to 15 per day/16 to > 35 per day). 
Barriers to SUD Treatment. The dependent variables for this study were perceived 
readiness, financial, structural, or stigma-related barriers to accessing initial or additional 
treatment for SUD within the past 12 months. Additional information on these barriers was 
previously described in Chapter 2, and is also available in Supplemental Table 2.1. Data were 
collected from 11 responses to create the four dichotomous barrier variables (yes/no), as 
demonstrated in previous studies.29,37,73 Respondents who said yes to one or more of the 
statements asked in any group were categorized as having perceived that barrier in the past 12 
months. 
3.2.4 Statistical Analysis  
LCA were conducted using Mplus 7.4, and multivariate regression analyses were 
conducted using SAS 9.4. The statistical analysis for this project occurred in three steps: 1) LCA 
was used to identify distinct classes of polysubstance use based on the unweighted frequency of 
past year substance use in the population, 2) individual cases were assigned to each class of 
polysubstance use, and 3) multivariate logistic regression was used to assess the association 
between predicted polysubstance class membership and perceived barriers to accessing treatment 
for substance use disorder.  
Step 1: Latent Class Analysis. LCA was utilized to identify hidden subpopulations of 
PSU that reflected distinct subgroups of substance use in a population of opioid-misusing 
individuals. LCA is unique from other “mixture model” types of cluster analysis as it is intended 
for use with categorical data.180 This is likely one of the reasons so many researchers have used 
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LCA to describe PSU, as substance use is typically measured at the categorical level.180 The 
LCA  model posits the existence of two or more unobservable population subtypes, or latent 
classes.180 A latent variable is measured indirectly by means of two or more observed variables 
within a population.163 Figure 3.1 illustrates a hypothetical latent variable. In Figure 3.1 an oval 
represents the latent variable, three squares (X1, X2, X3) represent the observed indicator 
variables used to measure the latent variable, and three circles (e1, e2, e3) represent the error 
component associated with each indicator variable. Note the arrows in this diagram show the 
causal flow stems from the latent variable to the indicator variable; this illustrates the concept 
that observed indicator variables measure latent variables, but they do not cause the latent 
variable.163 
In LCA the latent variable is categorical, or made up of classes, and each class has a set 
of probabilities for various responses to each indicator variable. The first equation in latent class 
modeling expresses the probability of observing response pattern y defined by:  
                         C          
P(Y=y) = Σ p (X=c)  x  p(Y=y/X=c) 
             c=1         
 
X represents the categorical latent variable, c is a specific latent class among C classes, y is the 
realization of the vector Y measuring the response patterns (X Y), p(X=c) represents the latent 
class probability, or the probability of belonging to class c, and p(Y=y/X=c) is the conditional 
response probability, or the conditional probability of having response pattern y, given that X belongs 
to specific class c.181 To illustrate, Figure 3.2 provides a schematic representation of a 3 class model. 
In Figure 3.2, the circle at top represents a case selected from the population at random, X represents 
latent classes 1-3, and Sx are three indicator variables. The probability of being in latent class 1 is 
represented by p(X=1), and p(Y=1/X=1) is the conditional probability of reporting indicator 1 for 
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latent class 1. For example, if p(X=1) = 0.4 and p(Y=1/X=1) = 0.2, then an individual chosen at 
random would have a 40% chance of belonging to latent class 1, and a 20% chance of reporting 
indicator 1 given membership in latent class 1.  
In the current study, LCA was performed using 16 indicators, which reported the unweighted 
prevalence of past-year substance use for: binge alcohol use, crack, cocaine, hallucinogens, heroin, 
inhalants, methamphetamines, marijuana, PPR, sedatives, stimulants, tranquilizers, and routes of 
substance administration (use of a needle to inject methamphetamines, cocaine, heroin, or other 
drugs).  
An important assumption of the LCA model is the assumption of local independence, or that 
conditional on the latent variable, the observed variables are independent.163 This assumption is 
visually represented in Figure 3.1; which shows that each indicator variable is a function of the latent 
variable and an error term, and only connected through the latent variable. Thus, if each indicator 
conditioning on the latent variable is independent, then the joint probability of all the elements making 
up the y vector for latent class c can be found by multiplying the individual probability parameters 
corresponding to a particular latent class. This leads to the second equation for LCA, which expresses 
the probability of observing the response pattern as a function of the latent class probabilities and the 
conditional response probabilities.  
                     C         K 
P(Y=y) = Σ p (X=c)  x  Π p(Yk=yk/X=c) 
        c=1        k=1 
 
In this equation, K represents the number of mutually independent indicator variables given the  
 






Step 2: Case assignment to latent classes. Membership in a latent class is determined 
through an individual’s posterior probability of belonging to class c given observed response 
pattern y. Posterior probabilities can be derived using Bayes’ theorem:  
P(X=c/Y=y) = p(Y=y/X=c) x p(X=c) 
             p(Y=y) 
 
Here, posterior probabilities are the product of the latent class probability p(X=c) and the 
conditional response probability p(Y=y/X=c) over the probability of a particular response pattern 
p(Y=y). Using posterior probabilities, cases are assigned to classes of the latent variable using 
modal assignment, where each case is assigned to the class with the largest posterior probability. 
Modal assignment is optimal, as it produces the smallest classification errors,181 and is 
particularly beneficial in instances where there may be little or no information in the item 
response probabilities.  In the context of the current study, the probability of PPR misuse alone 
would be expected to contribute little to class assignment, due to the high prevalence in the 
population, thus membership would be expected to rely more heavily on the latent class 
probability.  
Assessing LCA model fitness. The latent class model will be performed for multiple 
classes, thus it is important to choose the model which has the best empirical fit. As there is 
currently no standardized way to assess LCA model fitness, researchers suggest using a variety 
of statistical indicators to determine fitness. The current study utilized four evaluative indicators 
to determine which number of classes best fit the model, including: Sample-size adjusted 
Bayesian Information Criterion (BICSS), entropy, Lo-Mendell-Rubin likelihood ratio test (LRT), 
and the parametric bootstrapped likelihood ratio test (BLRT).  
Even using an optimal method for assigning class membership, it is possible that some 
individuals may be assigned to the wrong class. For this reason, it is important to assess the 
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separation between the classes, or how well the classes can be distinguished based on existing 
empirical information.181 This can be done by measuring how much membership of posterior 
probabilities deviate from uniform using entropy, a standardized measure of the accuracy of 
placing participants into classes based on their model-based posterior probabilities.163,182 Values 
for entropy range from 0 – 1, and larger values indicate better latent class separation and 
subsequently lower class error. 
 The sample size adjusted Bayesian Information Criterion was created to aid model 
selection by penalizing the number of factors in a model.163,183 Models with the lowest BICSS are 
considered to have the best fit.182 The LRT and BLRT are used to compare nested latent class 
models. LRT uses an approximation to the likelihood ratio test distribution, and BLRT also uses 
a likelihood-based technique, p-values for both tests can be used to compare the increase in 
model fit between the k-1 and k class models.183,184 
Step 3: Multivariate regression analysis. After determining the model with the best 
empirical fit, results of the LCA were exported to SAS 9.4. Chi-square analyses were used to 
determine differences in sociodemographic characteristics by class. Association between the 
PSU classes and each of the perceived barriers to accessing treatment for SUD (readiness, 
financial, structural, stigma-related) were assessed using multivariate logistic regression, 
adjusting for age, sex, race/ethnicity, sexual identity, education level, total family income, 
urbanicity, insurance type, survey year, self-reported health, severe psychological distress, and 
average cigarette use per day. All SAS analyses accounted for the complex sampling design of 
the NSDUH. Evaluative indicators used to assess regression model fit included the Log 





3.3.1 Study Cohort  
There were 6,095 insured respondents reporting past year opioid misuse. The cohort was 
evenly distributed among the age groups, with 26.0% aged 18-25, 24.1% aged 26-34, 27.9% 
aged 35-49, and 22.1% aged 50-64. Respondents were predominantly male (53.4%), white 
(69.6%), and heterosexual (89.4%), with some college or a college degree (62.3%), a total family 
income above $20,000 (78.4%), and lived in a large metro area (56.9%). The majority reported 
having private insurance (64.0%), over a quarter reported Medicaid (27.3%). Half of the 
respondents reported very good/excellent health (50.2%), yet nearly a third reported severe 
psychological distress occurring within the past year (31.7%).  
The majority of respondents reported past year misuse of PPR (97.5%), far fewer 
reported heroin use (8.4%). The majority of respondents reported use of tobacco (60.8%), while 
nearly half reported binge alcohol and marijuana use (53.1% and 56.4%, respectively).  
Tranquilizers were the second most often misused prescription medication (26.8%), followed by 
stimulants (20.4%), while few respondents reported misuse of sedatives (5.6%). Cocaine was the 
most often reported illicit substance (18.0%), followed by hallucinogens (16.0%), while very few 
reported past year misuse of methamphetamines (6.3%), crack (3.6%), and inhalants (4.0%). 
Approximately 12.3% of the sample reported any type of injection drug use within the past year, 
Heroin injection occurred most frequently (4.5%), followed by injection of other drugs (2.6%), 
methamphetamines (2.3%), and cocaine (1.6%).    
3.3.2 Number of Classes  
Fit statistics for classes 2-6 are described in Table 3.1. The three-class model was 
selected based on high entropy (0.837), and significant p-values from both the LMR and the 
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BLRT. The 3-class model was also deemed preferable to the 4-class model due to ease of class 
interpretability and theoretical considerations.  
3.3.3 Characteristics of the three-class model 
Table 3.2 reports the response probabilities for endorsing each type of substance use, 
categorized by most likely class membership for a three-class model, and Figure 3.3 illustrates 
the latent classes of past year PSU. Class 1 was deemed the “Heroin injectors with high PSU”, as 
individuals in this class had the highest probability of reporting illicit (heroin (89.5%), cocaine 
(54.4%), crack (33.3%), methamphetamines (37.0%)) and injection (cocaine (19.1%), heroin 
(57.3%), methamphetamines (27.6%), and other (29.7%)) substance use compared to other 
classes.  
Class 2 (“PPR users with low PSU”) contained the largest proportion of the study sample 
(n=4000, 64.2%), and was composed of individuals reporting misuse of PPR (99.4%), who 
reported moderate use of licit/near licit substances (binge alcohol (42.6%), marijuana (37.5%)), 
low use of illicit substances, and almost no injection substance use. 
Class 3 (27.9% of the sample) was the “PPR with high PSU” class, made up of 
individuals misusing PPR (99.8%) who also reported disproportionately high misuse of 
prescription medications (tranquilizers (52.6%), stimulants (50.2%)), licit/near licit substances 
(binge alcohol use (80.9%), marijuana (95.6%)), and several illicit substances (cocaine (46.6%), 
hallucinogens (47.8%)), but little to no injection substance use. 
3.3.4 Comparison of sociodemographic characteristics by latent class membership 
Table 3.3 reports sociodemographic characteristics of the study population by type of 
latent class PSU. The age distribution was significantly different in each class. Heroin injectors 
with high PSU were closer to middle age, with 33.5% between 26-34 and 26.5% between 35-49, 
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while the PPR users with high PSU had a higher proportion of older individuals, with 26.5% 
between 50-64 and 32.0% between 35-49. In contrast, the PPR users with low PSU had a 
disproportionately higher prevalence of younger respondents, as 51.7% reported being 18-25. In 
addition, while males were more prevalent among the Heroin injectors with high PSU (65.9%) 
and PPR users with high PSU (64.2%), females made up over half (51.1%) of the PPR users 
with low PSU.  
PPR users with low PSU and PPR users with high PSU appeared to be similar with 
respect to education level, total family income, and insurance type. Individuals in these classes 
were more likely to have some college (64.0%, 63.1%), report a total family income of more 
than $20,000 (81.6%, 75.7%), and were insured by private insurance (65.9%, 69.7%). In 
contrast, Heroin injectors with high PSU were more likely to have a lower education (51.9%), 
and make less than $20,000 (44.2%). Further, Heroin injectors with high PSU were far more 
likely to be Medicaid recipients (59.1%).  
3.3.5 Association between latent class membership and barriers to accessing treatment for SUD 
Table 3.4 reports the adjusted odds of perceiving a barrier to SUD treatment for each 
PSU class (odds ratios for all covariates provided in Supplemental Table 3.2). Compared to PPR 
users with low PSU, readiness barriers were significantly more likely to be perceived by both 
PPR users with high PSU (aOR=2.89, 95%CI=1.41-5.93) and Heroin injectors with high PSU 
(aOR=3.11, 95%CI=1.43-6.77). Additionally, Heroin injectors with high PSU also had 
significantly increased odds of perceiving structural (aOR=2.42, 95%CI=1.22-4.79) and stigma-






The findings of this study identified three distinct classes of PSU within a nationally 
representative sample of individuals reporting opioid misuse in the past year: (1) Heroin 
injectors with high PSU, (2) PPR users with low PSU and (3) PPR users with high PSU. The 
type of substances most often misused varied by class: whereas PPR users with low PSU only 
reported a high probability of PPR misuse, PPR users with high PSU were characterized by high 
probabilities of licit/near licit (binge alcohol and marijuana) and prescription drug misuse 
(tranquilizers, stimulants). In contrast, Heroin injectors with high PSU reported high 
probabilities of illicit (cocaine, crack, methamphetamines) and injection substance use, and 
moderate probabilities of licit/near licit (binge alcohol, marijuana) and prescription misuse (PPR 
tranquilizers, stimulants, and sedatives). The likelihood of perceiving barriers to accessing SUD 
treatment also varied between PSU classes. Compared to the PPR users with low PSU, both the 
Heroin injectors with high PSU and PPR users with high PSU class had significantly greater 
odds of perceiving a readiness barrier. Heroin injectors with high PSU also reported significantly 
increased odds of perceiving structural and stigma-related barriers to accessing SUD treatment. 
The findings of this study highlight how barriers to accessing SUD treatment differ by distinct 
PSU subgroups within the opioid-misusing population, and may require appropriately targeted 
interventions to help decrease barriers to accessing treatment for SUD.  
3.4.1 Differences between classes   
The classes of PSU in this study may differ from those of previous LCA for a variety of 
reasons. First, this study is unique as it provides patterns of PSU among opioid-misusing 
individuals in the U.S. In contrast to previous studies, which investigated patterns of PSU among 
heroin users,164,171 the current study reports patterns of PSU among individuals reporting past 
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year use of heroin, PPR misuse, or both. Further, the patterns of PSU are likely different as this 
study uses a nationally representative sample. This is different from previous studies, which 
recruited people who inject drugs (PWID),166,168,185,186 or recruited from only one urban city, 
where the increased availability of certain substances (i.e., methamphetamines, cocaine) might 
have influenced the observed patterns of PSU, but not be reflective of substance use trends 
throughout the nation168. 
 Previous U.S. studies have investigated the associations between patterns of PSU and 
various health-related outcomes, including: healthcare utilization,155 overdose training,185 risk 
behaviors (e.g., injection practices, sex risk behaviors, HIV/Hepatitis-C (HCV) risk 
factors),123,155,167,170,172,173 psychological distress,167 drug overdose,186 and mortality.165 This study 
is unique in that it examines the relationship between patterns of PSU and perceived barriers to 
accessing treatment for SUD, which may provide insight into what obstacles continue to persist, 
and which populations are most likely impacted. In addition, only one other U.S. study has 
investigated the association between insurance status and class of PSU; reporting a high 
prevalence (83%) of health insurance among a group of polysubstance using women, and no 
significant differences in the prevalence of health insurance by classes of PSU.155 The findings of 
the current study go further by identifying significant differences in types of insurance by classes 
of PSU; Heroin injectors with high PSU contained the highest proportion of Medicaid recipients, 
while private insurance was highly prevalent among PPR users with high PSU and PPR users 
with low PSU. The high prevalence of Medicaid recipients in the Heroin injectors with high PSU  
class relative to the other classes is consistent with the findings of previous literature, which 
show a high prevalence of heroin use or dependence among individuals with Medicaid.187 
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Understanding how type of insurance differs by class of PSU may further inform the discussion 
of how to decrease barriers to accessing SUD treatment, as discussed in more detail below.  
3.4.2 Substances of interest  
Binge Alcohol Use. Conditional probabilities for binge alcohol use were highest for PPR 
users with high PSU (80.9%). Previous studies have also reported the highest probabilities of 
binge alcohol use in classes characterized by heavy PSU. Lorvick et al. found that binge drinking 
was significantly higher in a “heavy polydrug class” where ≥ 75% of members reported use of 
heroin, crack, non-heroin opioids, and benzodiazepines, with moderate use of cocaine and 
methamphetamines.155 In addition, in an analysis of PSU among lifetime cocaine users, the 
highest probabilities of binge drinking were reported in a class with high probabilities of 
marijuana, prescription opioid, stimulant, and sedative misuse.188 
The comparably low probability of binge alcohol use among Heroin injectors with high 
PSU is also consistent with the results of previous studies, where the lowest conditional 
probabilities of alcohol use were reported in classes characterized by heroin injectors.170,171 Yet, 
while in the findings of the current study binge drinking appears to be lower among Heroin 
injectors with high PSU, research suggests co-occurring alcohol use is becoming more prevalent 
among heroin users. A 2015-2016 analysis assessing combinations of substance use among 
heroin users reported alcohol as one of the most simultaneously co-used substances with both 
heroin and prescription drugs.164 Further, a study of heroin and cocaine users in a methadone-
maintenance program reported that drinking alcohol was associated with heroin craving and use 
of other drugs.189 The moderate to high prevalence of binge alcohol use within each class 
highlights the importance of screening for alcohol use in all opioid-misusing individuals entering 
treatment for SUD, so that they may receive services best tailored to their needs.  
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Marijuana Use. The probability of past year marijuana use was relatively high for Heroin 
injectors with high PSU (71.3%) and PPR users with high PSU (95.6%). High probability of 
marijuana use among heroin users was expected based on the results of previous studies. Past 
month marijuana use was reported by 40-61.0% of PWID in the U.S.,155,164,185 and one analysis 
of heroin users in Cleveland, OH reported that marijuana was one of the most common 
simultaneously co-used substances with heroin.164 Previous studies in the U.S. have reported 
high probabilities of marijuana use among individuals who report both illicit drug and 
prescription opioid misuse,170,171,185,188 and two Canadian studies reported conditional 
probabilities of marijuana use ≥ 50% within all classes of opioid users.132,175 
Although the prevalence of marijuana use among PPR users with low PSU is comparably 
low (37.5%), it is noteworthy that marijuana is one of two substances of moderate use in the 
class containing the largest proportion of the population. This may be due to the rise in clinical 
evidence supporting the use of marijuana to treat opioid withdrawal, reduce opioid use/misuse, 
and improve outcomes for SUD treatment.190 Although findings of the current study show 
marijuana use is most prevalent among Heroin injectors with high PSU and PPR users with high 
PSU, future research should continue to monitor these patterns as legislation to decriminalize and 
legalize recreational use spread throughout the U.S.   
Tobacco use. Moreover, the findings of the current study are consistent with the 
conclusions of previous studies, which stated that while smoking has decreased in the overall 
population, it remains highly prevalent among opioid-misusing individuals.128 It is possible that 
SUD treatment facilities may continue to avoid addressing nicotine dependence, believing it may 
cause additional stress for patients. Yet studies have demonstrated that smoking cessation can be 
effectively carried out during methadone maintenance,128 and one systematic review concluded 
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that implementation of a smoking cessation intervention during SUD treatment often had no 
significant impact on opioid or illicit drug use.191 Although the American Society of Addiction 
Medicine recommends a tobacco use query and cessation counseling be performed during the 
diagnosis of OUD, they also state that further research on tobacco cessation during opiate 
treatment programs is needed before specific evidence-based recommendations can be made.90 
The high prevalence of tobacco use among these groups highlights the necessity of investigating 
tobacco use in these patients, in order to monitor and reduce use within this population. 
Surveillance of tobacco use among opioid-users could better inform the development and 
evaluation of interventions promoting smoking cessation. Future research should consider 
accounting for tobacco use when assessing patterns of substance use among opioid-misusing 
populations.  
3.4.3 Association between classes of PSU and barriers to accessing treatment for SUD 
Readiness Barriers. The Heroin injectors with high PSU and PPR users with high PSU 
were significantly more likely to perceive a readiness barrier to treatment compared to PPR users 
with low PSU. These findings are consistent with those of earlier studies reporting readiness and 
motivation to stop using opioids as a persisting issue. Over a third of opioid misusing adults 
throughout the U.S. report they are not yet ready to stop using opioids.86  Among PWID, not 
being ready for treatment, and not viewing drug use as a problem are common reasons for not 
seeking treatment for SUD.192 Education and targeted interventions to connect opioid-misusing 
individuals with treatment are crucial in order to increase enrollment in SUD treatment. By 
identifying distinct groups of opioid users with a high likelihood of perceiving readiness barriers 
(PPR users with high PSU and Heroin users with high PSU) the findings of this study could be 
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used to develop more targeted interventions that can be implemented in areas frequented by these 
high-risk populations.   
Structural Barriers. The heroin injectors with high PSU were nearly two and a half times 
more likely to perceive a structural barrier to treatment in comparison to PPR users with low 
PSU. One likely explanation is that heroin injectors with high PSU are more likely to be covered 
by Medicaid, as over half (59.1%) were Medicaid recipients, and as such may be more likely to 
experience coverage-related barriers to treatment access. Although Medicaid coverage has 
increased substantially among individuals with SUD following the implementation of the ACA, 
the supply of SUD treatment available to Medicaid covered individuals has not kept pace.21,38 
This is likely because many states’ Medicaid programs restrict coverage of addiction treatment; 
requiring prior authorization for medications used to treat opioid addiction or imposing lifetime 
treatment caps that limit accessibility.193,194 In addition, poor reimbursement rates in comparison 
to private insurance may lead to decreased acceptance of Medicaid among SUD treatment 
providers; between 2014-2017, only 52.0% of buprenorphine-prescribing physicians accepted 
Medicaid for buprenorphine-related office visits,194 and Saloner et al. found that opioid addiction 
treatment utilization was nearly 30% higher among Medicaid enrollees in states where Medicaid 
reimbursed methadone, compared to states with no public funding for methadone.195 Further 
research is needed to better understand the relationship between perceived barriers and SUD 
treatment Medicaid coverage policies.  
In addition, Heroin injectors with high PSU may face more barriers finding appropriate 
treatment. PWID often report medical196 and psychiatric197 comorbidities that may complicate 
their ability to find treatment for SUD. Although policies such as prescription guidelines and 
prescription monitoring programs may have contributed to the rise in PWID, treatment coverage 
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for PWID in the U.S. continues to be far below international standards, as the ratio between the 
availability of treatment services and the number of PWID who could use those services remains 
low.198 In addition, resources to address psychiatric comorbidity during treatment for SUD are 
often limited.199 One study assessing addiction treatment programs between 2004-2011 found 
only 18% were capable of dual diagnosis of addiction and mental health treatment.200 Taken 
together, these findings emphasize that additional work is needed to decrease structural barriers 
that prevent individuals with high heroin, PSU and injection substance use from accessing 
treatment for SUD.  
Stigma-Related Barriers. Heroin injectors with high PSU had three times the odds of 
experiencing a stigma-related barrier compared to PPR users with low PSU. Whereas non-
injecting individuals who misuse PPR may be able to conceal their addiction, PWID are more 
likely to bear physical symptoms (i.e., open sores, “track marks”) or comorbidities (i.e., HIV, 
HCV, Endocarditis) that reveal their addiction. Many PWID report experiencing stigma due to 
family, community, and healthcare professionals.201 Negative interactions with healthcare 
providers are a leading reason PWID are hesitant to access SUD treatment.96,97 In one study, 
PWID perceived attitudes from healthcare professionals that were based solely on their 
knowledge of the participants’ injection drug use, stating that they felt “looked down on” by 
medical personnel, and reporting that medical staff often prioritized care for others, placing 
PWID “at the back of the line”.97 In addition, clinician attitudes towards PWID could influence 
quality of care. Medical staff report that their colleagues are less supportive of harm reduction 
services for PWID,202 and a significant predictor of support for discriminatory behavior are the 
attitudes and concerns that clinicians have about PWID.67 In one study of syringe access 
programs, although 60.6% of PWID reported seeing a primary care provider within the past year, 
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results indicated they were not receiving adequate preventative services or education about harm 
reduction.203 Additional work remains to decrease the amount of stigma perceived by opioid-
misusing PWID. These findings provide further support for the conclusions of previous studies, 
which have called for continued efforts to educate clinicians and the community at large in order 
to destigmatize treatment for SUD. 
Financial barriers. PSU class was not significantly associated with perceiving a financial 
barrier to accessing treatment. In contrast to the previous results, this finding might reflect the 
success of current interventions. It was notable that PSU class was not significantly associated 
with perceiving a financial barrier to accessing treatment. As this study only included individuals 
with insurance, this result could indicate that provisions under the ACA to make coverage of 
SUD services equitable to other healthcare services are making SUD treatment more affordable 
for insured adults. This supports the results of a previous study, which reported a decrease in 
perceived financial barriers to accessing SUD treatment following implementation of the ACA.73  
3.4.4 Public health implications  
  First, understanding the relationship between patterns of PSU and access barriers can be 
used to inform public health efforts to address these barriers, and highlight appropriate locations 
for resource allocation. Heroin injectors with high PSU were most likely to perceive readiness, 
structural, and stigma-related barriers to accessing SUD treatment, therefore interventions to 
decrease these barriers should focus on places where Heroin injectors with high PSU are found, 
such as needle exchange sites, supervised injection sites, or clinics preventing the spread of 
HIV/HCV. In addition to harm reduction sites, efforts to decrease barriers and increase treatment 
connection might be provided at emergency departments. Previous literature shows that 
individuals with PSU patterns similar to Heroin injectors with high PSU and PPR users with 
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high PSU are more likely to be treated in an emergency room as compared to PPR users with low 
PSU. In one LCA identifying patterns of substance use among overdose survivors admitted to a 
U.S. emergency department between 2017-2018, a significant number of patients fell within the 
“mostly heroin overdose” (45%) or “opioid, polysubstance” (11%) classes, while less than a 
third (27.3%) fell into the “mostly non-heroin opioid overdose” class.188 Several studies have 
reported that interventions initiated in the emergency department (e.g., initiation of medication 
assisted treatment, peer support) to connect overdose survivors with treatment can increase the 
engagement in SUD treatment or harm reduction services following discharge.204–206 
3.4.5 Strengths and limitations  
Strengths. This study was the first to characterize patterns of PSU within a nationally 
representative population of opioid-misusing adults in the U.S. The NSDUH assures privacy and 
confidentiality of answers to increase the likelihood of honest reporting of illicit drug use and 
illegal activities, and the response rate for each of the three years included in this study were 
high, ranging between 69.7-67.1%.207  
As opposed to previous studies where substances were required to have a prevalence of 
15-20% to be included as an indicator variable in LCA,132,155,165,166,168,170 this study included past 
year use of all licit/near licit, illicit, and prescription misuse reported to the NSDUH. In addition, 
in contrast to all other U.S. studies investigating patterns of PSU, this study included information 
about tobacco use and smoking.  
Limitations. The findings of this study should also be viewed within the context of 
several limitations. First, the data are cross-sectional and derive from self-reported substance use 
within the past 12 months, which may be limited due to recall bias and/or social desirability bias. 
In addition, these patterns of PSU derived from indicators of past year substance use from a 
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nationally representative population. Thus, results may not be generalizable to specific cities or 
regions within the U.S. where increased availability of certain street drugs (e.g., crack, cocaine, 
methamphetamines) or legality of substance use (i.e. marijuana) might alter observed patterns of 
PSU.  
Second, the LCA did not account for the complex sampling design of the NSDUH, which 
may have resulted in biased parameters and underestimated standard errors.208 In addition, the 
findings of the current study may not directly compare to those of previous LCA due to variation 
in how alcohol use is captured. For example, several studies included indicators of any alcohol 
drinking or use,164,170,171 which makes it difficult to distinguish between less harmful occasional 
alcohol use and more problematic binge drinking. Additionally, the definitions for “binge 
drinking” varied, including “4 or more drinks on a single occasion”155 and “≥5 of more drinks in 
one sitting”.168 Only three studies used indicator variables for binge drinking as defined by the 
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (five drinks for men and four for 
women in one sitting).166,188,209 Future researchers should consider using the NIAAA definition 
of binge drinking to ensure comparability between studies, and aid the development of strategies 
to prevent opioid overdoses involving alcohol. 
Finally, these findings may be limited due to an inability to differentiate between all 
modes of drug administration (i.e., snorting, smoking), and the inability to differentiate between 
concurrent vs. simultaneous substance use. In addition, this study did not differentiate between 
misuse of prescription opioids primarily prescribed for pain (e.g., oxycodone, fentanyl, 






Participation in treatment is a necessary step towards ending opioid addiction. This study 
demonstrated an association between patterns of PSU and perceived barriers to accessing SUD 
treatment among opioid-misusing individuals. These findings highlighted a subpopulation of 
opioid users at increased odds of experiencing readiness, structural, and stigma-related barriers to 
accessing SUD treatment, and provided strong evidence that additional steps are necessary to 
decrease barriers to treatment perceived by individuals reporting high PSU. These findings also 
underscored the importance of re-evaluating the admissions process for SUD treatment, and 
providing further education to clinicians and the community to decrease stigma towards 
individuals with SUD. The current study added information to the contributions of previous 
literature that could be used to encourage the development of interventions that help opioid-
misusing individuals seeking SUD treatment to overcome the barriers that they are most likely to 
face. Decreasing perceived barriers to accessing care are necessary in order to increase 
enrollment in SUD treatment.  
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Chapter 4. Evaluating the impact of an out-of-hospital initiated opioid treatment 
connection program on the number of nonfatal opioid overdoses 24-months post 
intervention 
 
Background: The steady rise in opioid-related mortality has led to rise in interventions aimed at 
connecting opioid-misusing individuals to treatment for substance use disorder (SUD). On 
February 1st 2018 the Chesterfield Fire and EMS Community Paramedicine Program 
implemented an out-of-hospital intervention aimed at connecting survivors of nonfatal opioid 
overdose (OOD) to treatment for SUD. The objective of this study was to evaluate the 
association between the implementation of this out-of-hospital intervention and the trend of 
monthly nonfatal OOD in the county of implementation. 
Methods: We utilized EMS electronic patient care records in Virginia from February 1, 2016 to 
January 31, 2020. Incidents where naloxone was administered with patient improvement were 
included for Virginians aged 18-89. Two interrupted time series (ITS) analyses were conducted 
using Poisson regression to assess changes to the trend of monthly nonfatal OOD from pre-
intervention to post-intervention. Analyses included single ITS of Chesterfield County and 
multiple ITS comparing trends in both Chesterfield County and a comparable control county.  
Results: Of the 16,719 911 responses to a nonfatal OOD in Virginia during the study period, 
1,034 (6.0%) occurred in Chesterfield County and 879 (5.3%) in the control county. Single ITS 
showed an immediate decrease in nonfatal OOD by 0.33% each month (p=0.0857), and no 
statistically significant difference between the post-intervention trend and the pre-intervention 
trend (p=0.9195). There were no statistically significant differences in the pre-intervention level 
or trend of monthly nonfatal OOD between counties, indicating comparability. The post-
intervention level was approximately 0.18% lower for Chesterfield (p=0.5150), and the 
difference in the differences of slopes between counties from pre-to-post intervention was 0.02% 
(p=0.2404). 
Conclusions: These findings provide initial support for the effectiveness of an out-of-hospital 
intervention that links survivors of nonfatal OOD to treatment for SUD. 
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4.1 Introduction  
4.1.1 The Opioid Epidemic in Virginia 
In 2017, the opioid epidemic caused the deaths of 1,445 Virginians, an 8% increase in 
fatalities from 2016.210 Opioid-related incidents have burdened healthcare and public safety 
resources throughout the Commonwealth, resulting an annual average of 10,000 emergency 
department visits and 4,000 emergency medical services (EMS) responses211 in 2017, and one 
opioid-related criminal arrest every two hours.212 Accumulating costs from the impact of opioid 
misuse on public safety and other state services has had a broad impact on the Virginia’s 
economy, with one study estimating the per capita cost of the opioid epidemic at $1,624 per 
resident, equivalent to nearly 3% of the overall gross domestic product in Virginia.213 Although 
the continued needs of the opioid epidemic have pushed the General Assembly of Virginia to 
invest a great deal of money between 2017 and 2018214 to fund public health initiatives aimed at 
decreasing opioid-related morbidity and mortality, the steady increase in fatalities despite these 
efforts highlight the need to address potential gaps that may persist. 
4.1.2 VA Initiatives to Decrease Opioid-Related Morbidity 
Similar to many states throughout the nation, Virginia has acknowledged the serious 
consequences of the opioid epidemic, declaring that “a public health emergency resulting from 
opioid addiction exists in the Commonwealth, affecting the health and safety of Virginians” on 
November 21st, 2016.215 Virginia officials addressed the public health emergency through 
implementation of interventions aimed at preventing future addiction and decreasing overdose 
fatalities. To promote the appropriate use of controlled substances, in July of 2017 Virginia 
mandated all prescribers to register for the prescription monitoring program (PMP), an online 
database which enabled prescribers to monitor their patient’s use of controlled substances, and 
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more effectively deter potential misuse and diversion.216 To decrease deaths due to accidental 
overdoses, Virginia took steps to increase civilian access to the opioid-antidote naloxone. The 
Commonwealth medical director released standing order in 2016 which allowed for the over-the-
counter prescription of naloxone,217–219 and in 2017 the opioid overdose and naloxone education 
program REVIVE! was initiated, which dispensed naloxone at no cost through community 
trainings and local health departments throughout Virginia.220,221 Finally, to decrease the 
incidence of Human Immunodeficiency Virus (HIV) and Hepatitis C among injection drug users, 
in 2018 the Commonwealth opened two needle exchange programs.222–224  
Various key public health initiatives have been implemented successfully throughout the 
nation, each recommended by the Centers for Disease Control as a key strategy to decrease 
opioid overdose (OOD) morbidity and mortality.225 Despite these efforts, the number of opioid-
related fatalities in Virginia has continued to rise, from 1,284 in 2016 to 1,445 in 2017.210  
One explanation for the rise in deaths could be due to the increased presence of fentanyl 
in Virginia. As previously mentioned, fentanyl use has significantly increased throughout the 
nation since 2013, accounting for 77% of the total increase in deaths attributed to heroin.226 This 
trend was also reported in Virginia according to Attorney General Mark Herring, who stated in a 
press briefing that “fentanyl has become the biggest driver of the rise in overdose deaths in 
Virginia”.227 Deaths due to fentanyl in the Commonwealth have increased by 1,337% since 
2009227 and continue to rise, increasing by 23.4% from 2016 to 2017.228 
However, the upward trending of opioid-related fatalities could also be attributed to the 
policy emphasis on implementing initiatives rooted in primary and tertiary prevention-based 
approaches, rather than secondary prevention approaches which would emphasize screening and 
treatment. PMP are a primary prevention strategy, allowing surveillance of individuals who use 
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prescription opioids to prevent and deter further misuse; whereas both needle exchange and 
naloxone distribution programs represent tertiary prevention strategies, reducing either risk of 
blood-born pathogen transmission or risk of fatal overdose among individuals already misusing 
opioids.229,230 Although multiple studies have demonstrated the effectiveness of these strategies 
in decreasing opioid-related morbidity,225,229 these initiatives are ultimately limited in that they 
do not directly address treatment for opioid addiction. Virginia Governor Dr. Ralph Northam 
highlighted the importance of both treatment and prevention in a 2018 address to medical 
students discussing the opioid epidemic, emphasizing that state efforts to address the opioid 
crisis must involve both prevention and treatment, stating “…when prevention does fail, 
treatment works”.231 However, since this address no additional funds or programs have been 
initiated to increase access to treatment, and as 464,000 Virginians reported needing but not 
receiving treatment for substance use in 2016, additional initiatives to ensure better access to 
treatment were clearly warrented.232  
4.1.3 VA Initiatives to Increase Access to Addiction Treatment 
One program aimed at increasing access to addiction treatment for Virginians' was the 
Addiction Recovery and Treatment Services or ARTS program, implemented in April of 2017.214 
ARTS increased the number of available addiction treatment providers by making addiction 
treatment more cost effective for practitioner to provide, resulting in increased access to 
treatment for Medicaid members with opioid and other substance use disorders.214,233–235 
Following ARTS implementation the number of outpatient opioid treatment services in Virginia 
increased from 6 to 108,234 and evaluators reported a 51% increase in the treatment rate of 
Medicaid members with Opioid Use Disorder (OUD) over the first five months of the 
program.233 Though initially restricted due to the limited number of individuals covered by 
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Medicaid in a non-expansion state, access through ARTS is expected to further increase in 
January of 2019, when the expansion of Medicaid throughout the Commonwealth will increase 
Medicaid coverage to an additional 400,000 individuals.236   
In addition to expanding access to addiction recovery and treatment services for Medicaid 
recipients through ARTS, in May 2018 Governor Ralph Northam accepted a Federal grant of 
over 9.7 million dollars for the Department of Behavioral Health and Developmental Services, 
expected to help fund the Virginia Community Services Boards, which provide prevention, 
treatment, and recovery services to all Virginians.211  
4.1.4 Limitations to VA Initiatives 
While initiatives to improve access to addiction treatment in Virginia have yielded 
promising results, limitations remain. The continued rise of opioid-related fatalities despite 
implementation of the ARTS program could be attributed to the restricted number of individuals 
eligible for Medicaid who qualify for participation in the program.214 Although increased access 
is expected with Medicaid expansion in 2019, the benefits of the program will remain limited 
only to individuals covered by Medicaid, likely excluding a significant proportion of the opioid 
addicted population who are in need of addiction treatment but are either not qualified for 
Medicaid,237 or are eligible but unable to enlist.238 Further, although the 2014 passage of the 
Patient Protection and Affordable Care Act (ACA) expanded insurance to many Americans,45 
passage of the ACA was not associated with increased use of treatment for substance use 
disorder (SUD) among individuals with substance use disorders,21 indicating additional 
initiatives to engage these individuals may still be warranted.38 Low treatment enrollment in this 
population could persist due to logistical barriers to access (ie. transportation),239 or lack 
knowledge on where to access these resources.21 Finally, these interventions will likely have 
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little impact on individuals declining to seek treatment due to motivational or stigmatization 
barriers, which are more common among the insured population.22 
4.1.5 Healthcare Partnerships Connecting Addicts with Treatment 
To better address these remaining gaps, additional efforts should focus on connecting 
opioid-abusing individuals to treatment and supporting them throughout the treatment process. 
Governor Northam highlighted the importance of these programs by allocating additional 
funding from his $9.7 million dollar Federal grant to “support the development of partnerships 
with the hospital that will connect individuals who overdose with peers in recovery”.211 Although 
hospital partnerships connecting individuals with peers during the recovery period have 
demonstrated early success,240 limiting inclusion to hospital-based partnerships could potentially 
exclude a significant proportion of the opioid-abusing population, as prehospital research reports 
63-69% of patients refuse transport to the hospital following an OOD,241,242 or depart prior to 
physician discharge against medical advice.243 Further, as studies suggested that individuals with 
access to naloxone could be less likely to  call for assistance following an overdose,244 the 
increased availability of naloxone in the Commonwealth could lead to a decrease in the number 
of individuals seeking treatment at a hospital following an overdose. Thus, to expand the effort 
of treatment-connection initiatives in the opioid-abusing community, it may be beneficial to 
explore not only hospital partnerships, but also partnerships with public safety personnel, 
specifically, emergency medical services (EMS).  
4.1.6 Feasibility of EMS Personnel Connecting Patients to Addiction Treatment  
The recent expansion of EMS personnel into non-emergent healthcare roles further 
supports their partnership viability. Although designed to respond to emergency situations, many 
EMS agencies now participate in mobile integrated health care or community paramedicine; 
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programs which enable EMS personnel to provide individualized patient care in a non-emergent 
role.245 Many of these programs were designed to use EMS personnel to help patients navigate 
the healthcare system to find and access available resources.246 Individualized to the needs of the 
patient, community paramedicine programs provide a variety of services, including: management 
of chronic diseases, assessing and addressing hazards in the home, or accessing and arranging 
medical appointments.245,246 Research has demonstrated these programs are extremely effective 
at connecting patients with healthcare resources, resulting in decreased use of EMS, decreased 
visits to the emergency department, decreased hospital readmissions.247,248 Further, participants 
of these programs report being highly satisfied with the care they receive from the community 
paramedics.246 The success of these programs demonstrate EMS personnel can effectively 
connect patients with healthcare resources in the community, providing further support for the 
use of EMS personnel in connecting opioid-misusing patients with treatment. 
Although few studies have reported the implementation of overdose related intervention 
and treatment connection programs by public safety personnel, emerging results from these 
studies are promising. A 2017 survey in Massachusetts reported that 21% of public safety 
agencies were administering some form of outreach program for opioid addicts.249 Administered 
primarily by law enforcement and fire, some interventions reported encouraging results; with one 
program of police-led referrals successfully placing 75% of those seeking addiction treatment 
services into care.250 However, no study has yet evaluated the effectiveness of programs using 
EMS personnel to connect patients with treatment for SUD. The promising results of programs 
implemented by other public safety officials further support the feasibility of a program 




4.1.7 Study Aims and Hypothesis  
Although various interventions have aimed to increase the availability of addiction 
treatment throughout the nation, many individuals in need of addiction treatment remain without. 
Programs where health-care providers connect opioid-misusing individuals to addiction 
treatment and peers in addiction recovery are currently recommended, but underutilized in the 
out-of-hospital environment. While early research has demonstrated that public-safety outreach 
programs can be effective in referring individuals to addiction treatment facilities, at the date of 
this writing no programs have evaluated the effectiveness of an intervention implemented by 
EMS personnel. This is the first evaluation of an out-of-hospital intervention implemented by 
EMS personnel to link survivors of OOD with treatment for substance use disorders. 
The objective of this study was to evaluate the impact of the Chesterfield Fire & EMS 
Community Paramedicine Peer Support and Treatment Connection (PSTC) program on the trend 
of monthly nonfatal OODs, 24 months after implementation of the program. We hypothesized 
that Chesterfield County would see a significant decrease in the level of monthly nonfatal OODs 
immediately after implementation of the PSTC program, and a gradual decrease in the trend of 
monthly nonfatal OODs over the 24-month post-intervention period, as compared to the 24-
month pre-intervention period. Additionally, we hypothesized that pre- to post implementation 
differences in the trend of monthly nonfatal OODs would be significantly lower for Chesterfield 
County in comparison to an adjacent “control” county. 
4.2 Methods  
4.2.1 Study Design  
This study used a quasi-experimental interrupted time-series design to compare changes 
in the trend of monthly nonfatal OODs before and after implementation of the PSTC program. 
Observations of nonfatal OODs were collected simultaneously in Chesterfield County and an 
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adjacent county over four years and split into two time periods: pre-intervention (February 1st 
2016 – January 31st 2018) and post-intervention (February 1st 2018 – January 31st 2020).  
4.2.2 Study Intervention  
On February 1st 2018 the Chesterfield County Fire and Rescue Community Paramedicine 
Program partnered with a peer support specialist for an opioid outreach intervention that aimed 
to connect survivors of nonfatal OOD treated by Chesterfield EMS with an addiction treatment 
program within Chesterfield County or the surrounding area. Following an EMS response for an 
OOD, a Chesterfield Community Paramedic and peer support specialist follow up with the 
patient by phone to schedule a meeting. During the meeting, the team encourages the individual 
to seek treatment for opioid misuse, and offers to help connect them to local treatment programs 
within the county or surrounding area. If the individual agrees, the peer support specialist works 
one-on-one to enroll them in treatment programs. The services provided by the community 
paramedicine team and the peer support specialist vary, as services are individualized to meet the 
needs of each participant. The team may call to follow up with the participant if they need 
counseling or may attend the mental health evaluations with the participant at their request. Once 
a participant completes a mental health evaluation, they become eligible for the community 
health services provided by the Chesterfield County Community Services Board, and their 
participation in the program ends.  
4.2.3 County Populations and Emergency Medical Services  
Chesterfield County is the 4th most populous county in Virginia, with an estimated 2018 
population of 348,556. Chesterfield County Fire and Rescue is the largest provider of EMS in 
Chesterfield County, and responded to 69.6-81.2% of the nonfatal OODs during the study 
period. In addition to Chesterfield Fire and EMS, EMS are provided by four volunteer rescue 
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squads, and a large metropolitan service from a neighboring county, which responded to 19.3-
21.0% of nonfatal OOD during the study period.  
The control county was chosen due to the similarities in demographic characteristics and 
the provision of EMS within the county. Supplemental Table 4.1 summarizes the population 
characteristics and OOD characteristics for each county in 2018. Located adjacent to 
Chesterfield County, the control county is the 5th most populous county in Virginia, with an 
estimated 2018 population of 329,261. Similar to Chesterfield, the control county-run fire 
department is the primary provider of EMS, and responded to 65.4-75.3% of nonfatal OODs 
during the study period. EMS in the control county is also supplemented by five volunteer rescue 
squads, and a large metropolitan service in a neighboring county, which responded to 12.6-
23.4% of nonfatal OOD during the study period. Up to the time of this writing, the county-run 
fire department had not yet implemented a program aimed at connecting survivors of nonfatal 
OOD with resources for addiction treatment. 
4.2.4 Data Source and Study Population 
Adults between the ages of 18 and 89 were eligible for inclusion in the study if they were 
treated by EMS personnel for a nonfatal OOD in Chesterfield County or the control county 
during the study period (February 1st 2016 – January 31st 2020). Incidents meeting criteria that 
were the result of a non-911 response (interfacility transport, standby, assist) were excluded from 
analysis. 
Data was extracted from EMS electronic patient care reports (ePCRs) for all incidents of 
nonfatal OODs within both counties occurring between February 1st, 2016 and January 31st 2020. 
An ePCR is required to be completed by a Virginia certified paramedic or emergency medical 
technician after every EMS incident in the Commonwealth of Virginia, then submitted to the 
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Virginia Pre-Hospital Information Bridge program located within the Virginia Department of 
Health Office of Emergency Medical Services, Division of Trauma and Critical Care.251 All 
protected health information was removed using de-identification methods recommended by the 
U.S. Health and Human Services.252  
Annual estimates for county population were obtained from the Centers for Disease 
Control and Prevention Wide-ranging Online Data for Epidemiologic Research.  
4.2.5 Measures 
The primary dependent variable of the study was the monthly count of nonfatal OOD for 
Chesterfield County and the control county between February 1st, 2016 and January 31st 2020. 
A nonfatal OOD was defined as any EMS incident where an individual was administered 
naloxone and their condition “improved”.  
The primary independent variable was the study period: the period of February 1st 2016 – 
January 31st 2018 (pre-intervention period) vs. the period of February 1st 2018 – January 31st 
2020 (post-intervention period).   
Demographic and incident-related measures were extracted to assess differences in 
demographic and incident-related characteristics between the two counties. These included: sex 
(male or female), age in years (18-24, 25-34, 35-44, 45-54, 55-64 or ≥65), and race (Non-
Hispanic White, Non-Hispanic Black, or other (Hispanic, Asian, American Indian or Alaska 
native, native Hawaiian or other Pacific Islander, “other race”, or selections of multiple races)). 
Incident-related characteristics included year of overdose, location of incident (private residence, 
residential facility, or public location), route of naloxone administration (intranasal (IN), 
intravenous (IV), other (intramuscular, intraosseous, oral, endotracheal tube, topical, 
other/miscellaneous), or combined (receiving naloxone through a combination of IN, IM, IV or 
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other routes)) and the dose of naloxone administered in milligrams (mg) (0.4-0.9 mg, 1.0-1.9 mg, 
2.0-2.9 mg, 3.0-4.9 mg, or ≥ 5.0 mg)).  
4.2.6 Analytic Strategy  
All statistical analyses were performed using R Studio v3.6.3. Descriptive statistics were 
calculated to assess differences in the distribution of demographic and incident-related 
characteristics between the two counties, using T-tests for continuous variables and Pearson Chi-
square tests for categorical variables.  
Interrupted time-series analysis using a Poisson regression model was used to assess the 
changes in the level and trend of monthly nonfatal OOD before and after implementation of the 
PSTC program. Development of the model and analysis were based on an interrupted time series 
regression tutorial developed by Bernel et. al.253 
This times series analysis was performed using two models: a single interrupted time 
series (SITSA) model which assessed changes in the pre- and post-intervention trend of monthly 
nonfatal OOD before and after intervention implementation in Chesterfield, and a multiple 
interrupted time series (MITSA) model, which assessed changes in the pre- and post-intervention 
trends of monthly nonfatal OOD between Chesterfield County and the control county.  
The equation for SITSA is based on segmented linear regression:254  
yT = β0 + β1T + β2X + β3XT + ε 
In this model, yT is the average of nonfatal OODs at month T, T is the continuous time (in 
months) from the start of the pre-intervention period on February 1st 2016 to the end of the 
implementation period on January 31st 2020. X is a binary variable that indicates intervention 
implementation (0=pre-intervention, 1=intervention), and XT is an interaction term that 
represents time after intervention implementation. β0 is an estimate of the baseline count of 
68 
 
monthly nonfatal OODs, β1 estimates the average change in monthly nonfatal OOD during the 
pre-intervention period, β2 estimates the level change in monthly nonfatal OOD immediately 
after intervention implementation, β3 estimates the average change in monthly nonfatal OOD  
from pre- to post-intervention, and ε is an error term that represents random variability that was 
not accounted for in the model. In addition, β1+3 was calculated to show change in the average 
monthly nonfatal OOD during the post-intervention period. 
The equation for the MITSA model is an expansion of the SITSA equation that adds in a 
control series. This control series was used to assess whether the level and slope changes 
observed in the treatment county (Chesterfield) are significantly different from those observed in 
the control county.254 
yT = α + β1T + β2X + β3XT + β4Z + β5ZT + β6ZX + β7ZXT + ε 
In this equation, Z is a binary variable that codes treatment status (1=treatment, 0=control), and 
ZT, ZX, and ZXT are all interaction terms among the aforementioned variables.255 In this model 
the purpose of coefficients β0 – β3 are the same as those described in the SITSA model, but now 
provide estimates for the control county. β4 estimates the pre-intervention difference in the level 
of the outcome between treatment and control, β5 estimates the pre-intervention difference in the 
slope of the outcome between treatment and control, β6 indicates the difference between 
treatment and control in the level immediately following introduction of the intervention, and β7 
indicates the difference between treatment and control groups in the trend of the outcome 
variable after initiation of the intervention compared to the pre-intervention trend.255  
Results of the observed and predicted trends for each model were plotted to visually 
demonstrate the curve-shifting. The Pearson-based dispersion statistic was used to assess for 
overdispersion in each model.256 If overdispersion was found, models were adjusted in a 
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quasipoisson model, which allows variance in the model to be proportional rather than be equal 
to the mean. In addition, autocorrelation, or the correlation of a variable with itself at different 
time periods, was assessed in both the SITSA and MITSA models through visual inspection of 
the sample autocorrelation and residual plots, and use of the Breusch-Godfrey test statistic.  
4.2.7 Statement of Ethics 
This study utilized de-identified data; no variables in the assessment could be used to 
identify patients, or indicate status of vulnerable patient populations (i.e., pregnant women or 
prisoners). This study was therefore approved as exempt from review by the Institutional Review 
Board at Virginia Commonwealth University, ID= HM20016514. 
4.3 Results 
Of the 16,719 911 responses to a nonfatal OOD during the study period, 1,034 (6.0%) 
occurred in Chesterfield County and 879 (5.3%) in the control county. Table 4.1 describes the 
demographic and incident-related characteristics for nonfatal OODs by county. In comparison to 
nonfatal OOD responses in the control County, Chesterfield County reported a higher prevalence 
of female patients (38.9% vs. 33.1%), a lower prevalence of Non-Hispanic Black patients (22.5% 
vs. 32.1%), and reported more overdoses occurring in a private residence (67.9% vs. 59.5%). 
Further, in contrast to patients in the control county, patients in Chesterfield were predominately 
administered naloxone intra-nasally (60.4% vs. 28.2%). Additionally, the average total dose of 
naloxone administered to patients was significantly higher in Chesterfield (3.2 mg vs. 1.8 mg), 
and over half (54.2%) of Chesterfield patients received a dose of 3.0mg or higher, compared to 
15.5% of patients in the control county.  
The dispersion statistic for the SITSA quasipoisson model was 2.18, indicating that the 
conditional variance was at least two times larger than the conditional mean. Adjusted 
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estimates showing trends in observed and predicted monthly nonfatal OOD in Chesterfield 
County are included in Table 4.2, and are further illustrated in Figure 4.1. Pre-adjustment 
estimates were included in Supplemental Table 4.2. The pre-intervention trend (β1) in 
Chesterfield County showed an increase in monthly nonfatal OODs by about 0.01% each 
month. There was an immediate decrease in monthly nonfatal OOD by 0.33% following 
implementation of the intervention, however this estimate was not statistically significant 
(p=0.0857). Additionally, there was no statistically significant difference between the post-
intervention trend and the pre-intervention trend (p=0.9195), and the estimated post-
intervention trend (β1+3) appeared very similar to the pre-intervention trend, showing an 
increase in monthly nonfatal OOD by 0.02%. On visual inspection the residuals appear to be 
randomly distributed, showing no patterns (Supplemental Figure 4.1), further the correlogram 
for autocorrelation revealed no lags in time where autocorrelation was statistically significant 
(Supplemental Figure 4.2). 
The dispersion statistic for the MITSA quasipoisson model was 2.02, indicating that 
the conditional variance was approximately two times larger than the conditional mean. 
Adjusted estimates of the MITSA are reported in Table 4.3, and predicted pre- and post-
intervention trends for both counties are presented in Figure 4.2. Unadjusted estimates are 
available for comparisson in Supplemental Table 4.3.  
Table 4.3 reports the results of the MITSA between Chesterfield and the control county. 
Monthly averages of nonfatal OOD for both counties are plotted in Figure 4.2. In contrast to 
Chesterfield, the pre-intervention trend (β1) in the control county showed a decrease in monthly 
nonfatal OOD by .003% each month (p=0.7512). Immediately following initiation of the 
intervention, monthly nonfatal OOD decreased by 0.15% (p=0.4702). There was no statistically 
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significant difference between the pre-intervention trend and the post-intervention trend (β3), 
showing an approximate 0.02% increase in the monthly average nonfatal OODs (p=0.0953). 
Chesterfield and the control county did not show any statistically significant differences in the 
pre-intervention level (β4) or trend (β5) of monthly nonfatal OOD, indicating that the two series 
were comparable prior to intervention implementation. There were no statistically significant 
differences in the pre- to post-intervention differences in level (β6) or trend (β7) between 
Chesterfield and the control county. The post-intervention level was approximately 0.18% lower 
for Chesterfield compared to the control county (p=0.5150), and the difference in the differences 
of slopes between counties from pre-to-post intervention was 0.02% (p=0.2404).  
Residuals from the MITSA appeared to be randomly distributed with no clustering or 
patterns (Supplemental Figure 4.3), and visual inspection for autocorrelation revealed no lags in 
time where autocorrelation was statistically significant (Supplemental Figure 4.4). 
4.4 Discussion  
The SITSA found no statistically significant pre- to post-intervention differences in the 
average monthly number of nonfatal OODs in Chesterfield County. An immediate reduction was 
observed in the average monthly nonfatal OOD following program implementation, however this 
difference was not statistically significant. Additionally, there was no significant difference in 
the trend of average monthly nonfatal OOD from pre- to post-intervention. In the MITSA, there 
was a difference observed in the pre- to post-intervention trends for the control county. The post-
intervention trend showed a minimal increase in monthly nonfatal OOD compared to the trend of 
nonfatal OOD pre-intervention, however this difference was not statistically significant. There 
were no statistically significant differences for both the pre-intervention trend and the pre-
intervention level between Chesterfield and the control county. Chesterfield saw a greater 
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reduction in monthly nonfatal OODs immediately following program implementation compared 
to the control county, however this difference was not statistically significant. In addition, there 
was no statistically significant difference in the differences between the pre- to post-intervention 
trends for each county.  
4.4.1 Results of MITSA model 
The trend of monthly average nonfatal OODs in Chesterfield County did not significantly 
change from pre-intervention to post-intervention. A lack of significant change between the pre-
intervention and post-intervention trends usually indicate that the intervention under 
investigation may not be sustainable over time. However, the MITSA showed the trend of 
nonfatal OODs in the control county significantly increased from pre-intervention to post-
intervention. The key assumption when using MITSA is that change in the level or trend in the 
outcome would be similar for the control and for the treatment group, had the intervention not 
been implemented255. This suggests that implementation of the intervention may have delayed or 
slowed a rise in the trend of nonfatal OODs in Chesterfield County that would have been 
expected if the intervention had not been implemented.  
4.4.2 Unmeasured potential confounders impacting analysis  
Overall, the differences between the two counties for the estimates of pre- to post-
intervention change for the level and trend of nonfatal OODs were not statistically significant. 
This could be due to the co-occurring implementation of other opioid-related interventions, 
which may impact one county more than the other. The key assumption behind comparison with 
a control county, is that confounding omitted variables would affect the treatment and control 
groups similarly.255 Yet it is possible that some of the co-occurring opioid-related interventions 
had a differential impact on the counties. 
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The disproportionate prevalence of fentanyl between the counties could impact the 
monthly average of nonfatal OODs. In Virginia, fentanyl-related mortality spiked at the 
beginning of the study period, increasing by 177.3% from 2015 to 2016.228 Data from the Office 
of the Virginia Medical Examiner show that the 2016-2018 fentanyl-related mortality rate per 
100,000 was 8.0 to 13.8 in Chesterfield, compared to 6.4 to 11.2 in the control county.257 Ideally, 
fentanyl would be accounted for through stratification,258 which would allow for evaluation of 
the differential impact of the intervention on subpopulations of nonfatal OODs with and without 
fentanyl. Unfortunately, EMS ePCRs lack a standardized way of reporting fentanyl involvement 
during a nonfatal OOD. Even if documented, the accuracy of self-reported data would still be 
questionable, as many individuals may not know the heroin they purchased had been cut with 
fentanyl.259 Further research is needed to determine whether this intervention would have a 
differential impact on the monthly average nonfatal OODs after controlling for fentanyl. 
Legislation increasing the availability of naloxone in Virginia, such as naloxone 
distribution programs and over-the-counter availability of naloxone, may also impact the 
counties differently.260 Prevalence of bystander naloxone may impact the monthly average of 
nonfatal OOD, as individuals administering naloxone may be less willing to call 911, either out 
of fear for police involvement,261,262 or because they feel they can handle the overdose 
themselves.263,264 Thus, prevalence of bystander naloxone may increase the likelihood of an 
individual overdosing without summoning 911, which would underestimate the true count of 
nonfatal OODs in the community. Accounting for the presence of bystander naloxone in Virginia 
would be challenging. To the author’s knowledge, the REVIVE! program does not keep a record 
of the number of residents receiving naloxone training, or the number of naloxone units 
distributed in each county. However, prior naloxone administrations, or naloxone administered 
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prior to the arrival of EMS personnel, could be used as a proxy to account for the presence of 
bystander naloxone within the community. A previous analysis of 2016-2018 nonfatal OODs in 
both counties revealed that Chesterfield had a disproportionately high number of prior naloxone 
administrations compared to the control county. Thus, it is possible that individuals in 
Chesterfield could be less likely than those in the control county to summon 911 to the scene of 
an overdose. This would result in the underestimation of the true count of OOD each month, and 
have a differential impact on the monthly average of nonfatal OODs in the two counties. 
4.4.3 Strengths 
 This study has several strengths. Interrupted time series allows researchers to perform a 
robust analysis of a dependent variable without incurring the cost and work associated with a 
randomized control trial.258 The interrupted time series approach enables us to evaluate the effect 
of the Chesterfield intervention program on the monthly average of nonfatal OODs in 
Chesterfield County, while accounting for the pre-implement trend for the monthly average of 
nonfatal OODs.  
An additional strength of this study is the inclusion of a non-equilivant control group in 
our MITSA, which enhances the internal validity of the analysis by allowing the researcher to 
control for omitted confounding variables.253,255  
4.4.4 Limitations  
However, the results of this study should also be viewed in the context of several 
limitations. The data used for this study were de-identified and unlinked, meaning it is possible 
that an individual could have been treated multiple times during the study period. However, it is 
unlikely that the occurrence of a “repeat overdose” would differ between counties. In addition, 
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the analysis was limited to records from two counties in the Commonwealth of Virginia, which 
may limit the generalizability of these results to other jurisdictions. 
In addition, on January 1st, 2017 the Virginia Office of EMS stopped accepting ePCRs 
from EMS agencies not using data submission standards for National Emergency Medical 
Services Information System version 3.4. This initially resulted in the exclusion of all incidents 
from Chesterfield Fire and EMS, and all volunteer rescue squads in Chesterfield County for 
January and February of 2017. While Chesterfield Fire and EMS was able to provide researchers 
with the cumulative number of eligible cases for those two months, data from volunteer rescue 
squad responses were not available; which may have slightly underestimated the true count of 
nonfatal OODs in Chesterfield County for those two dates.  
Further, previous researchers have questioned the accuracy of using EMS naloxone 
administrations as a proxy for nonfatal OODs, reporting low sensitivity and positive predictive 
value for the use of naloxone administrations alone.265 While our definition (i.e., EMS patients 
who received naloxone and improved) increased precision by excluding false-positive cases (i.e., 
OOD patients who received naloxone with no improvement), it likely still underestimates the 
true number of nonfatal overdoses during the study period, by excluding any individual with an 
OOD who was not administered naloxone. This definition also would have excluded individuals 
who had an OOD but did not improve until additional naloxone was administered at the hospital, 
or individuals who did not improve due to comorbidities secondary to an OOD or 
pharmacokinetic effects of a secondary drug unaffected by naloxone administration.  
Finally, the accuracy of these findings are dependent upon the accuracy of the ePCRs 




Implementation of an opioid treatment connection program did not appear to have a 
statistically significant impact on the monthly average of nonfatal OODs. Although the monthly 
average of nonfatal OODs was reduced following program implementation, this association was 
not statistically significant. Increasing the number of months for post-intervention analysis may 
be needed to more accurately determine whether this intervention has a sustained effect on the 
average number of nonfatal OODs each month. Further research is needed to evaluate the 
effectiveness of public health interventions implemented by EMS personnel as a part of the 
public health strategy to address the opioid crisis.   
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Chapter 5: Conclusions  
Increasing the enrollment of opioid-misusing individuals into treatment for substance use 
disorder (SUD) is necessary in order to achieve sustainable long-term decreases in opioid-related 
morbidity and mortality. For this reason, addressing barriers to accessing treatment for SUD is 
critically important to increase treatment enrollment. The goal of this dissertation was to produce 
results that would provide insight into the persisting barriers to accessing SUD treatment in 
opioid-misusing individuals by: testing the association between type of opioid misuse and 
perceived readiness, financial, structural, and stigma-related barriers in insured adults reporting 
past year opioid misuse (Chapter 2);  identifying classes of past year polysubstance use among 
opioid-misusing adults in the U.S. and assessing the association between polysubstance use 
classes and perceived barriers to accessing treatment for SUD (Chapter 3); and evaluating the 
effectiveness of an out-of-hospital opioid treatment connection program on the number of 
nonfatal opioid overdoses 24-months post intervention (Chapter 4). 
5.1 Type of opioid misuse and perceived barriers to accessing treatment 
Chapter 2 provided insight into the degree to which those reporting opioid misuse and 
perceived a need for treatment perceived a barrier to accessing treatment. Results from Chapter 2 
indicated that 3.7% of insured Americans reporting past-year opioid misuse perceived at least 
one barrier to accessing treatment for SUD. Further, individuals with combined heroin and 
prescription pain reliever (PPR) misuse were nearly 3 times more likely to perceive readiness 
and structural barriers, and nearly 4 times more likely to perceive stigma-related barriers to 




Results from Chapter 2 could help inform the strategic placement of public-health 
interventions aimed at connecting opioid-misusing individuals to treatment for SUD. For 
example, interventions could be implemented in areas with a traditionally high prevalence of 
heroin injectors or individuals with high polysubstance use (PSU), such as clean needle syringe 
services, supervised injection sites, homeless shelters, halfway houses, and the emergency 
department. In addition, these findings should serve to further support guidelines for the routine 
screening of substance misuse currently recommended by the American Society of Addiction 
Medicine5. Individuals with high PSU and people who inject drugs are at greater risk for 
psychiatric and medical comorbidities, and often seek emergency or acute care to treat those 
conditions.266 Thus, increasing identification of SUD through routine screening during treatment 
for psychiatric and medical comorbidities may increase access to treatment for SUD in these 
populations. 
5.2 Type of opioid misuse and perceived barriers to accessing treatment 
In Chapter 3, latent class analysis (LCA) identified three distinct classes of PSU within a 
nationally representative sample of individuals reporting opioid misuse in the past year: (1) 
Heroin injectors with high PSU, (2) PPR users with low PSU and (3) PPR users with high PSU. 
Compared to PPR users with low PSU, Heroin injectors with high PSU and PPR users with high 
PSU had 3 times the odds of perceiving readiness barriers, and Heroin injectors with high PSU 
were also nearly 2.5 times more likely to perceive structural barriers and 3 times more likely to 
perceive stigma-related barriers. No subpopulations in this opioid-misusing population had a 
statistically significant association with financial barriers.  
Taken together, the results of Chapter 3 further demonstrate how accounting for patterns 
of PSU during the assessment of treatment outcomes is crucial for the design and implementation 
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of interventions addressing barriers to accessing treatment. For example, in Chapter 2, 
individuals with H+PPR were more likely to perceive barriers to treatment compared to 
individuals with PPR. However, in Chapter 3 classifying individuals into groups based on their 
past year substance use enabled the identification of two distinct subgroups of individuals with 
H+PPR that were more likely to perceive barriers to accessing treatment (PPR users with high 
PSU, Heroin injectors with PSU). The unique sociodemographic characteristics and substance 
use profiles of these two subgroups could be used to more efficiently target interventions aimed 
at connecting individuals to treatment. For example, an intervention addressing readiness barriers 
may increase opportunities for individuals in both subgroups to interact with social workers or 
peer recovery specialists, who could provide counseling or motivational interviewing and discuss 
resources for treatment. Although some locations, such as the emergency department, might 
offer access to both populations, this intervention could better target Heroin injectors with high 
PSU through additional implementation at harm reduction services (e.g., clean needle exchange 
sites, supervised injection facilities). 
Results of the LCA also identified a class of PSU that might be difficult to connect to 
treatment, further supporting the recommendation for physicians to increase routine screening of 
SUD. PSU users with high PSU might be more difficult to access for two reasons: 1) PPR users 
with high PSU would not be expected to participate in the same harm reduction initiatives as 
Heroin injectors with high PSU (e.g., clean needle exchange sites, supervised injection 
facilities), and 2) the high prevalence of older adults and lack of any physical signs of addiction 
may make this group ‘less identifiable’ as individuals with a SUD. Thus, increasing routine 
screening for substance misuse at emergency and acute care facilities could increase the 
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identification of this hard-to-reach group that accounted for nearly a quarter of the population, 
and enable clinicians to link those individuals to needed resources.  
5.3 Type of opioid misuse and perceived barriers to accessing treatment 
 Chapter 4 discusses an out-of-hospital intervention implemented by emergency medical 
services (EMS) personnel and a peer support specialist that connects survivors of nonfatal opioid 
overdoses (OOD) to treatment for SUD. Initial findings of this study demonstrated that, on 
average, the County of implementation (Chesterfield) showed an immediate decrease in the 
monthly number of nonfatal OOD compared to a control county where the intervention was not 
implemented. In addition, the difference in the differences in pre- to post-intervention trend 
showed that the control county had a slight increase in the post-intervention trend of monthly 
opioid overdoses. However, Chesterfield County saw no difference in the trend between pre- and 
post-intervention. Thus, although this small sample yielded small effect sizes and no statistical 
significance, these findings suggest that in the absence of the intervention, Chesterfield County 
may have also experienced an increase in monthly nonfatal OODs. Therefore, these results 
provide preliminary evidence that encourages the use of out-of-hospital opioid treatment 
connection programs to prevent further increases in the trend of monthly nonfatal OODs. 
Many of the services offered by Chesterfield County and other EMS-implemented 
programs directly address the barriers identified in the current study. Similar to Chesterfield 
County, community paramedics in a Houston program conduct home visits with a peer recovery 
coach, who uses motivational interviewing to address readiness barriers in survivors of nonfatal 
OOD268. Peer support and recovery specialists could also be used to help patients overcome 
stigma-related barriers, as they can offer counseling and support through the treatment initiation 
process based on their own lived experiences.   
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Out-of-hospital programs can also address financial and structural barriers by connecting 
opioid-misusing individuals to available treatment programs most appropriate for their care. In 
Chesterfield, a community paramedic is responsible for determining treatment availability and 
ensuring program participants are placed in treatment appropriate for their care. This is also 
similar to previous programs; in Houston, community paramedics are also responsible for 
following up with patients and scheduling all clinical visits.268  
 In addition, collaborations formed between out-of-hospital programs and treatment 
facilities may further decrease barriers to treatment access by enabling program patients to gain 
immediate access to treatment. For example, Chesterfield program participants initially had a 10-
day waiting period to receive a mental health evaluation necessary for entering treatment. 
However, six months after program implementation, participants no longer had to wait to receive 
this evaluation. Other EMS programs prevent structural delays to accessing treatment by taking it 
upon themselves to initiate the initial treatment. In Houston, patients enrolled in the program 
following an outreach visit are assessed by a nurse practitioner and provided with a one or two-
week prescription for suboxone as interim treatment until the patient can be connected to a long-
term program268. In New Jersey, paramedics can request permission from medical oversight 
physicians to provide buprenorphine to eligible patients immediately following an overdose269.  
To date, many of the out-of-hospital programs currently available to address barriers to 
accessing treatment for SUD are still in the pilot stages, and at the time of this project, none have 
assessed the effects of program participation on treatment or population-level outcomes. In this 
respect, the final aim of this project is unique as it offers findings for the association between 
implementation of an out-of-hospital intervention and a population level outcome (nonfatal 
opioid overdoses). Other programs have reported difficulty evaluating the effects of their 
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program on treatment outcomes due to small sample sizes269 or difficulty obtaining data due to 
data-sharing agreements and/or privacy concerns.268 Future researchers should continue to 
evaluate the effects of out-of-hospital programs on treatment outcomes.   
5.4 Conclusions  
Although barriers to accessing treatment for SUD continue to persist following 
implementation of the ACA, the development and implementation of public-health interventions 
can be targeted towards the subpopulations most likely to perceive barriers. The findings of this 
project identify these subpopulations, and also report encouraging initial findings for an out-of-
hospital intervention that might be used to address these barriers. Future research should expand 
upon the findings of this project through continued evaluation of innovative intervention 
programs that can be used to help opioid-misusing individuals overcome persisting obstacles and 



























APPENDIX A: Tables and Figures 
 
Table 1.1: Public Health Initiatives Addressing the Opioid Epidemic in the United States  
Initiative Aim Effectiveness Implementation 
PRIMARY PREVENTION  
Prescription Drug Monitoring 
Programs  
Allow physicians and pharmacists access to a 
patient’s history of controlled substance 
prescriptions to prevent aberrant drug-seeking by 
the patient (visits to multiple providers) or 
aberrant prescribing practices by doctors7 
Studies have suggested that PMP are associated with 
significant declines in visits to multiple providers47, and 
correlated with declines in overall opioid prescribing in states 
requiring PMP utilization48 
All 50 states have PMP 
• 23 mandate clinician 
enrollment 
• 13 require use prior to 
writing a prescription7 
Prescription Limits  
Limit the number of opioid pills written in an 
initial prescription to decrease the risk of 
diversion and physical dependence and reduce the 
overall volume of prescriptions7 
No studies were found which evaluate effectiveness of state 
prescription limits, but studies of hospital-based prescriber 
limits have been associated with modest reductions in 
mortality270 
25 states have enacted 
prescription limits7 
Prescription Drug Take-Back 
Programs  
Allow easy disposal of leftover medications to 
reduce availability of unused controlled 
medications at risk for diversion or misuse49 
Take-back programs only gather a small fraction of existing 
opioids, and are not likely have a minimal impact on reducing 
unused prescription opioids within a community49 
At least 40 states publicize 
locations for collection 
boxes7 
TERTIARY PREVENTION  
Overdose Education and 
Naloxone Distribution Programs  
Distribute naloxone to community laypersons and 
individuals at high risk of opioid overdose to 
prevent overdose deaths50 
Overdose education programs are effective in improving 
knowledge related to recognizing and responding to an 
overdose, and bystanders and individuals who use opioids can 
administer naloxone to reverse an opioid overdose51,52 
There are NDPs in 15 states 
and DC46, or 8% of U.S. 
counties53 
Over-the-counter availability of 
Naloxone  
Increase availability of naloxone to opioid-users 
and laypersons to increase access in the event of 
an opioid overdose7 
Pharmacies in states with standing orders stock naloxone and 
dispense it without a prescription54, and adoption of naloxone 
access laws has been associated with significant reduction in 
opioid-related deaths55 
49 states allow OTC 
prescription of naloxone7† 
Good Samaritan Laws  Enable bystanders to an opioid overdose to call 911 without fear of being arrested7 
Good Samaritan laws decrease the proportion of  opioid-related 
deaths, but not significantly55, Good Samaritan laws were also 
not associated with an increase in the use of prescription 
opioids55  
39 states have enacted GSLs7 
Syringe-Needle Access Programs Limit the spread of blood borne infections by providing injection drug users with clean needles7 
Evidence suggests that access to syringe exchange programs 
decreases the risk of disease transmission7, though some 
studies report less effectiveness at preventing Hepatitis C 
infection46 
41 states have syringe access 
programs7  
Supervised Drug Consumption 
Venues 
Enable use of pre-obtained drugs in hygienic 
settings where trained staff are able to respond to 
overdoses, decreasing risk of fatal overdose56 
Overdoses were rare (one per 1,287 injections), but were 
successfully reversed by program staff. Participants in the 
program also reported more hygienic disposal of syringes57  
None‡ 
Abbreviations: GSL=Good Samaritan laws, NDP=naloxone distribution programs, OTC=over the counter, PMP=prescription monitoring programs 
†Nebraska is the only state that does not allow over-the-counter prescription of naloxone 















 N (%w) N (%w) N (%w) N (%w) 
Age      
18-25 years   2783 (26.0) 43 (15.0)‡ 2566 (26.1)‡ 174 (29.1)‡ 
26-34 years 1451 (24.1) 42 (33.0)‡ 1286 (23.2)‡ 123 (35.0)‡ 
35-49 years 1386 (27.9) 23 (20.5)‡ 1288 (28.3)‡ 75 (23.3)‡ 
50-64 years 475 (22.1) 19 (31.5)‡ 440 (22.4)‡ 16 (12.7)‡ 
Sex     
Male  3067 (53.4) 77 (67.4)† 2762 (52.4)† 228 (64.5)† 
Female  3028 (46.6) 50 (32.6)† 2818 (47.6)† 160 (35.5)† 
Race/ethnicity     
Non-Hispanic White 3979 (69.6) 90 (72.2) 3587 (69.2) 302 (75.9) 
Non-Hispanic Black 664 (10.2) 13 (14.8) 635 (10.1) 16 (8.8) 
Hispanic 572 (6.3) 10 (4.0) 535 (6.5) 27 (4.2) 
Other 880 (13.9) 14 (9.2) 823 (14.1) 43 (11.2) 
Sexual identity     
Heterosexual 5188 (89.4) 110 (90.8) 4760 (89.6) 318 (86.7) 
Lesbian, gay or bisexual 841 (10.6) 15 (9.2) 764 (10.4) 62 (13.3) 
Education level     
HS graduate or less 2544 (37.4) 79 (55.8)‡ 2252 (36.2)‡ 213 (48.9)‡ 
Some college-graduate  3551 (62.6) 48 (44.2)‡ 3328 (63.8)‡ 175 (51.1)‡ 
Total family income      
< $20,000 1590 (21.6) 65 (56.4)‡ 1390 (20.0)‡ 135 (33.6)‡ 
> $20,000-$49,000 4505 (78.4) 62 (43.6)‡ 4190 (80.0)‡ 253 (66.4)‡ 
Urbanicity      
Large metro  2707 (56.9) 62 (64.0) 2481 (56.7) 164 (56.7) 
Small metro  2224 (30.7) 43 (27.5) 2026 (30.7) 155 (32.8) 
Non-metro  1164 (12.4) 22 (8.5) 1073 (12.6) 69 (10.5) 
Insurance type      
Private insurance 3704 (64.0) 41 (33.7)‡ 3527 (66.6)‡ 136 (35.0)‡ 
Medicaid 1882 (27.3) 74 (58.3)‡ 1588 (24.8)‡ 220 (55.7)‡ 
Otherb 509 (8.7) 12 (8.0)‡ 465 (8.7)‡ 32 (9.5)‡ 
Survey year      
2015 2190 (34.5) 33 (24.2) 2029 (34.8) 128 (32.4) 
2016 1988 (34.3) 53 (37.6) 1795 (34.0) 140 (37.4) 
2017 1917 (31.3) 41 (38.2) 1756 (31.2) 120 (30.2) 
Self-reported health     
Fair/poor 2971 (49.8) 87 (71.9)‡ 2664 (48.9)‡ 220 (56.1)‡ 
Excellent/very good 3123 (50.2) 40 (28.1)‡ 2915 (51.1)‡ 168 (44.0)‡ 
Severe psychological distressc     
No < 13 3877 (68.3) 72 (57.5)‡ 3622 (69.6)‡ 183 (50.9)‡ 
Yes ≥ 13 2218 (31.7) 55 (42.5)‡ 1958 (30.4)‡ 205 (49.1)‡ 
Past year IDU      
No  5366 (87.7) 50 (38.6)‡ 5195 (92.4)‡ 121 (29.8)‡ 
Yes 729 (12.3) 77 (61.4)‡ 385 (7.6)‡ 267 (70.2)‡ 
Additional SUD       
None  3863 (67.7) 83 (69.2)‡ 3606 (69.0)‡ 174 (45.5)‡ 
1 additional SUD 1573 (23.3) 24 (17.7)‡ 1433 (22.9) ‡ 116 (32.5)‡ 
2 additional SUD 449 (6.4) 15 (10.4)‡ 373 (6.0)‡ 61 (11.4)‡ 
3 or more SUD 197 (2.6) 5 (2.7)‡ 158 (2.1)‡ 34 (10.6)‡ 
%w=weighted percent, H+PPR=heroin and prescription pain reliever use, HS=high school, H=heroin use only, IDU=injection drug use, N=sample size, 
NSDUH=National Survey on Drug Use and Health, PPR=prescription pain relievers use, SUD=substance use disorder. 
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001 
aComprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race 
bComprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”  





Figure 2.1: Perceived barriers by type of opioid misuse among respondents who reported at least one 





Table 2.2: Adjusted odds ratios for perceived barriers to accessing substance use disorder treatment in 
the past year by insured adults with past year opioid misuse (NSDUH 2015-2017) (N=6,029) 
 Readiness Barrier Financial Barrier Structural Barrier Stigma-Related Barrier 
 aORa (95% CI) aORa (95% CI) aORa (95% CI) aORa (95% CI) 
Age      
18-25 years   Referent  Referent Referent Referent 
26-34 years 1.19 (0.58-2.42) 1.85 (0.81-4.24) 1.89 (1.07-3.33)* 1.03 (0.52-2.06) 
35-49 years 1.12 (0.59-2.12) 1.28 (0.61-2.69) 1.14 (0.58-2.21) 0.90 (0.35-2.31) 
50-64 years 0.52 (0.20-1.36) 0.25 (0.03-2.52) 0.73 (0.22-2.43) 0.58 (0.12-2.76) 
Sex     
Male  0.81 (0.43-1.51) 0.88 (0.49-1.57) 0.77 (0.40-1.52) 0.78 (0.42-1.44) 
Female  Referent Referent Referent Referent 
Race/ethnicity     
Non-Hispanic White Referent Referent Referent Referent 
Non-Hispanic Black 0.43 (0.18-1.05) 0.69 (0.18-2.69) 0.82 (0.35-1.94) 0.46 (0.08-2.71) 
Hispanic 1.10 (0.49-2.48) 1.22 (0.34-4.32) 1.98 (0.85-4.58) 1.84 (0.60-5.62) 
Othera 1.12 (0.57-2.19) 0.17 (0.05-0.54)† 1.14 (0.47-2.76) 0.70 (0.26-1.88) 
Sexual identity     
Heterosexual Referent Referent Referent Referent 
Lesbian, gay, or bisexual 1.70 (1.00-2.90)* 1.17 (0.54-2.50) 1.52 (0.79-2.92) 1.36 (0.64-2.88) 
Education level     
HS graduate or less Referent Referent Referent Referent 
Some college-graduate 1.40 (0.83-2.37) 0.78 (0.36-1.67) 0.87 (0.48-1.57) 1.37 (0.58-3.27) 
Total family income      
< $20,000 1.31 (0.73-2.33) 1.85 (0.79-4.33) 1.16 (0.60-2.23) 2.82 (1.43-5.56)† 
> $20,000  Referent Referent Referent Referent 
Urbanicity      
Large metro  Referent Referent Referent Referent 
Small metro  0.78 (0.43-1.41) 0.95 (0.50-1.77) 0.94 (0.57-1.57) 1.88 (0.97-3.65) 
Non-metro  0.91 (0.47-1.75) 1.17 (0.52-2.65) 1.33 (0.66-2.65) 1.77 (0.63-4.93) 
Insurance type      
Private insurance Referent Referent Referent Referent 
Medicaid 1.54 (0.88-2.70) 2.32 (0.88-6.16) 1.66 (0.66-4.15) 1.06 (0.36-3.13) 
Otherb 3.12 (1.43-6.81)† 1.25 (0.52-3.01) 2.03 (1.05-3.94)* 0.50 (0.19-1.27) 
Survey year      
2015 Referent Referent Referent Referent 
2016 0.78 (0.41-1.49) 0.75 (0.37-1.52) 1.16 (0.60-2.26) 0.64 (0.24-1.75) 
2017 1.22 (0.65-2.28) 1.02 (0.52-2.01) 0.80 (0.44-1.46) 0.98 (0.52-1.84) 
Self-reported health     
Excellent/very good  Referent Referent Referent Referent 
Fair/poor 1.25 (0.70-2.21) 1.04 (0.59-1.82) 1.51 (0.97-2.36) 1.33 (0.59-3.00) 
Severe psychological distressc     
No < 13 Referent Referent Referent Referent 
Yes ≥ 13 3.02 (1.55-5.90)† 2.45 (1.05-5.70)* 2.90 (1.53-5.49)† 2.90 (1.42-5.92)† 
Past year IDU      
No  Referent Referent Referent Referent 
Yes 1.43 (0.54-3.81) 1.85 (0.62-5.46) 1.00 (0.44-2.27) 1.34 (0.47-3.80) 
Additional SUD   1.60 (1.29-1.98)‡ 1.25 (1.08-1.44)† 1.34 (1.11-1.62)† 1.14 (0.86-1.49) 
Type of opioid misuse      
PPR Referent Referent Referent Referent 
HO 1.08 (0.26-4.46) 1.98 (0.39-9.97) 0.89 (0.15-5.27) 2.25 (0.42-12.14) 
H+PPR  2.80 (1.08-7.27)* 2.03 (0.89-4.60) 3.27 (1.26-8.46)* 3.98 (1.42-11.21)* 
%w=weighted percent, aOR=adjusted odds ratio, H+PPR=heroin and prescription pain reliever use, HS=high school, HO=heroin use only, IDU=injection drug use, N=sample size, 
NSDUH=national survey on drug use and health, PPR=prescription pain relievers use, SUD=substance use disorder. 
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001 
aComprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race 
bComprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”  




Supplemental Table 2.1: Reasons why individuals felt they didn’t need treatment or additional 
treatment in the past year (N=382) 
Barrier  Explanation  N (%W) Overall†  
Readiness 
Barrier  Because not ready to stop use 21 (4.6) 4.6 
Financial 
Barrier 
Because of cost 11 (2.1) 6.2 Because no insurance 17 (4.3) 
Structural 
Barrier 
Because no transportation 8 (2.0) 
4.9 
Because treatment wanted not offered 6 (1.7) 
Because No openings in the program 6 (1.2) 
Because didn’t have time 6 (1.4) 
Because didn’t know where to go 4 (0.8) 
Stigma 
Barrier 
Because neighbors have negative opinion 13 (3.2) 
4.4 Because have negative effect on job 14 (2.6) 
Because didn’t want others to find out 7 (1.5) 
These responses are given for the question: “Which of these statements explain why you did not get the treatment or 





Supplemental Table 2.2: Bivariate associations between predisposing, enabling, and need 
characteristics with perceived treatment barriers among insured adults with past year opioid misuse 
(NSDUH 2015-2017) (N=6,029) 
 Readiness Barrier Financial Barrier Structural Barrier Stigma-Related Barrier 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Age      
18-25 Years   Referent  Referent Referent Referent 
26-34 Years 1.13 (0.62-2.05) 1.79 (0.86-3.74) 1.76 (1.05-2.95)† 0.88 (0.51-1.52) 
35-49 Years 0.83 (0.48-1.43) 1.10 (0.57-2.13) 0.84 (0.42-1.69) 0.67 (0.28-1.61) 
50-64 Years 0.33 (0.12-0.88)* 0.23 (0.02-2.24) 0.48 (0.16-1.44) 0.39 (0.09-1.65) 
Sex      
Male  0.74 (0.43-1.26) 0.84 (0.50-1.40) 0.69 (0.38-1.25) 0.67 (0.37-1.22) 
Female  Referent Referent Referent Referent 
Race/Ethnicity     
Non-Hispanic White Referent Referent Referent Referent 
Non-Hispanic Black 0.45 (0.21-0.98)* 0.66 (0.20-2.17) 0.87 (0.38-2.00) 0.36 (0.08-1.75) 
Hispanic 1.15 (0.53-2.52) 1.30 (0.32-5.24) 2.04 (0.85-4.87) 1.61 (0.50-5.20) 
Other 1.06 (0.59-1.91) 0.19 (0.06-0.59)* 1.12 (0.43-2.94) 0.56 (0.21-1.50) 
Sexual Identity     
Heterosexual Referent Referent Referent Referent 
Lesbian, Gay, or Bisexual 2.67 (1.74-4.12)‡ 1.63 (0.84-3.19) 2.35 (1.27-4.35)† 2.21 (1.07-4.57)* 
Education Level     
Less than HS or HS grad Referent Referent Referent Referent 
Some college, AS, or CG 1.19 (0.72-1.95) 0.67 (0.33-1.34) 0.69 (0.37-1.27) 1.22 (0.54-2.79) 
Total family income      
< $20,000 1.81 (1.12-2.92)* 2.55 (1.30-5.03)† 2.01 (1.20-3.38)† 3.05 (1.71-5.45)† 
> $20,000  Referent Referent Referent Referent 
Urbanicity      
Large metro  Referent Referent Referent Referent 
Small metro  1.03 (0.59-1.81) 1.31 (0.73-2.36) 1.17 (0.71-1.92) 2.27 (1.15-4.46) 
Non-metro  1.11 (0.63-1.94) 1.68 (0.70-4.02) 1.62 (0.77-3.42) 2.04 (0.72-5.74) 
Insurance Type      
Private Insurance Referent Referent Referent Referent 
Medicaid 2.47 (1.53-4.00)* 2.73 (1.56-4.82)† 3.79 (2.16-6.64)† 1.29 (0.74-2.22) 
Othera 3.54 (1.73-7.25)* 2.95 (1.06-8.17)† 2.28 (0.85-6.10) 1.61 (0.54-4.79) 
Year      
2015 Referent Referent Referent Referent 
2016 0.88 (0.47 – 1.68) 0.82 (0.40-1.68) 1.26 (0.64-2.46) 0.72 (0.27-1.98) 
2017 1.41 (0.77 – 2.57) 1.53 (0.61-2.19) 0.92 (0.50-1.69) 1.13 (0.58-2.21) 
Self-Reported Health     
Excellent/Very Good  Referent Referent Referent Referent 
Fair/Poor 1.70 (1.05-2.74)* 1.49 (0.94-2.37) 2.17 (1.34-3.50)† 1.67 (0.84-3.36) 
Severe psychological distress     
No < 13 Referent Referent Referent Referent 
Yes ≥ 13 5.51 (3.13-9.73)‡ 3.85 (1.73-8.60)† 4.73 (2.55-8.77)‡ 4.31 (2.07-8.96)† 
Past Year IDU      
No  Referent Referent Referent Referent 
Yes 3.67 (1.88-7.18)† 4.41 (2.24-8.70)‡ 18.12 (9.90-33.17)† 3.30 (1.66-6.56)† 
Additional SUD   1.90 (1.60-2.25)‡ 1.52 (1.33-1.73)‡ 1.60 (1.38-1.86)‡ 1.42 (1.19-1.71)† 
Past Year Opioid Misuse      
PPR  Referent Referent Referent Referent 
HO 1.56 (0.46-5.32) 3.74 (0.88-15.81) 1.29 (0.21-7.90) 3.14 (0.70-14.02) 
H+PPR  6.20 (3.20-12.01)† 5.34 (2.76-10.27)* 5.91 (3.11-11.22)† 5.60 (2.68-11.69)* 
HO=heroin use, PPR=pain reliever use, H+PPR= heroin and pain reliever use, SUD=substance use disorder, IDU=injection drug use, 
HS=high school, N=sample size, %w=weighted percent, NSDUH=national survey on drug use and health, OR=odds ratio, 95% CI=95% 
confidence interval 





Figure 3.1: Schematic representation of the latent variable 




Figure 3.2: Schematic representation of the latent class model  




Table 3.1: Latent class analysis model fit statistics for classes 2-6 
Classes BICss Entropy p-value for LMRa Loglikelihood Npar 
p-value for 
BLRTa 
2-CLASS 55384.4 0.787 <.0001 -27600.8 33 <.0001 
3-CLASS 52734.0 0.837 <.0001 -26228.6 50 <.0001 
4-CLASS 52502.9 0.709 <.0001 -26066.0 67 <.0001 
5-CLASS 52121.0 0.747 0.0001 -25827.9 84 <.0001 
6-CLASS 52078.8 0.768 0.2054 -25759.8 101 <.0001 
BICss=Sample Size Adjusted Bayes Information Criteria, BLRT=Bootstrapped Likelihood Ratio Test, LCA=Latent Class Analysis, LMR=Lo-Mendell-Rubin 
Adjusted Likelihood Ratio Test, Npar=Number of parameters  
aLMR and BLRT compare the increase in model fit between the k-1and k class models. Significant values indicate that the model has a statistically better fit than 
the model that preceeded it. 
 
Table 3.2: Conditional probabilities of past year substance use among individuals reporting past year opioid 






 (n=473, 7.8%) 
C2: PPR users 
with low PSU 
 (n=4000, 65.6%) 
C3: PPR users 
with high PSU 
 (n=1622, 26.6%) 
Licit/Near licit Substance Use  n (%) n (%c) n (%c) n (%c) 
Binge alcohol  3235 (53.1) 188 (39.8) 1704 (42.6) 1312 (80.9) 
Marijuana 3437 (56.4) 337 (71.3) 1500 (37.5) 1551 (95.6) 
Prescription Drug Misuse     
PPR 5934 (97.5) 350 (74.1) 3976 (99.4) 1619 (99.8) 
Tranquilizers 1627 (26.8) 202 (42.7) 548 (13.7) 853 (52.6) 
Stimulants 1242 (20.4) 122 (25.8) 276 (6.9) 814 (50.2) 
Sedatives 340 (5.6) 49 (10.3) 136 (3.4) 151 (9.3) 
Illicit Substance Use     
Heroin 511 (8.4) 423 (89.5) 32 (0.8) 63 (3.9) 
Cocaine 1097 (18.0) 257 (54.4) 44 (1.1) 756 (46.6) 
Crack 221 (3.6)  158 (33.3) 0 (0) 57 (3.5) 
Hallucinogens 976 (16.0) 113 (23.8) 48 (1.2) 775 (47.8) 
Inhalants 243 (4.0) 38 (8.0) 44 (1.1) 152 (9.4) 
Methamphetamines 385 (6.3) 175 (37.0) 44 (1.1) 157 (9.7) 
Injection Drug Use      
Used Needle to Inject Cocaine  98 (1.6) 90 (19.1) 0 (0) 3 (0.2) 
Used Needle to Inject Heroin 277 (4.5) 271 (57.3) 0 (0)  0 (0) 
Used Needle to Inject Methamphetamines  142 (2.3) 131 (27.6) 0 (0) 8 (0.5) 
Used Needle to Inject Other Drug  159 (2.6) 140 (29.7) 8 (0.2) 6 (0.4) 
%c=Conditional probability of class membership, N=Sample size, NSDUH=National survey on drug use and health, PPR=Prescription pain reliever, 
PSU=Polysubstance use 





Figure 3.3:  Latent classes of past year polysubstance use  




Table 3.3: Sociodemographic characteristics of insured opioid-misusing adults by latent class of 
polysubstance use (NSDUH 2015-2017) (N=6,095) 
 TOTAL 
(N=6,095) 
C1: Heroin injectors 
with high PSU 
 (N=473)  
C2: PPR users with 
low PSU 
(N=4000) 
C3: PPR users with high 
PSU 
(N=1622)  
 N (%w) N (%w) N (%w) N (%w) 
Age‡     
18-25 years   2783 (26.0) 178 (20.7) 1495 (19.0) 1110 (51.7) 
26-34 years 1451 (24.1) 150 (33.5) 987 (22.6) 314 (26.0) 
35-49 years 1386 (27.9) 105 (26.5) 1119 (32.0) 162 (14.4) 
50-64 years 475 (22.1) 40 (19.4) 399 (26.5) 36 (7.9) 
Sex‡     
Male  3067 (53.4) 284 (65.9) 1830 (48.9) 953 (64.2) 
Female  3028 (46.6) 189 (34.1) 2170 (51.1) 669 (35.8) 
Race/ethnicity†     
Non-Hispanic White 3979 (69.6) 354 (73.1) 2480 (68.0) 1145 (73.8) 
Non-Hispanic Black 664 (10.2) 29 (11.6) 532 (11.2) 103 (6.2) 
Hispanic 572 (6.3) 39 (4.2) 386 (6.6) 147 (6.3) 
Othera 880 (13.9) 51 (11.1) 602 (14.2) 227 (13.6) 
Sexual identity‡     
Heterosexual 5188 (89.4) 397 (89.2) 3470 (90.9) 1321 (84.6) 
Lesbian, gay or bisexual 841 (10.6) 68 (10.8) 484 (9.1) 289 (15.4) 
Education level‡     
HS graduate or less 2544 (37.4) 274 (51.9) 1620 (36.0) 650 (36.9) 
Some college-graduate  3551 (62.6) 199 (48.1) 2380 (64.0) 972 (63.1) 
Total family income‡      
< $20,000 1590 (21.6) 198 (44.2) 939 (18.4) 453 (24.3) 
> $20,000-$49,000 4505 (78.4) 275 (55.8) 3061 (81.6) 1169 (75.7) 
Urbanicity      
Large metro  2707 (56.9) 199 (56.1) 1796 (57.5) 712 (55.0) 
Small metro  2224 (30.7) 174 (31.2) 1439 (30.0) 611 (32.9) 
Non-metro  1164 (12.4) 100 (12.7) 765 (12.5) 299 (12.1) 
Insurance type‡      
Private insurance 3704 (64.0) 147 (31.4) 2463 (65.9) 1094 (69.7) 
Medicaid 1882 (27.3) 283 (59.1) 1211 (25.2) 388 (22.9) 
Otherb 509 (8.7) 43 (9.5) 326 (9.0) 140 (7.4) 
Survey year      
2015 2190 (34.5) 132 (28.8) 1463 (34.8) 595 (35.3) 
2016 1988 (34.3) 180 (36.3) 1283 (34.1) 525 (34.0) 
2017 1917 (31.3) 161 (34.9) 1254 (31.1) 502 (30.7) 
Self-reported health‡     
Fair/poor 2971 (49.8) 303 (63.7) 1976 (50.0) 692 (44.3) 
Excellent/very good 3123 (50.2) 170 (36.3) 2023 (50.0) 930 (55.7) 
Severe psychological distressc‡     
No < 13 3877 (68.3) 240 (52.1) 2725 (72.7) 912 (59.3) 
Yes ≥ 13 2218 (31.7) 233 (47.9) 1275 (27.3) 710 (40.7) 
Past year tobacco use‡     
No 2037 (39.2) 26 (8.2) 1789 (49.4) 222 (15.6) 
Yes 4058 (60.8) 447 (91.8) 2211 (50.6) 1400 (84.4) 
Average cigarette use per day 
for past 30 days‡ 
    
Never used/don’t smoke 2990 (53.8) 59 (16.6) 2411 (63.3) 520 (34.9) 
<1 – 1 per day 572 (7.7) 26 (6.1) 278 (6.0) 268 (14.3) 
2 to 5 per day  834 (12.3) 6 (15.2) 437 (9.9) 331 (19.4) 
6 to 15 per day  893 (12.5) 153 (25.7) 442 (9.5) 298 (18.1) 
16 to > 35 per day  803 (13.6) 169 (36.4) 430 (11.3) 204 (13.4) 
%w=weighted percent, HS=high school, N=sample size, NSDUH=National survey on drug use and health, PPR=prescription pain relievers use, PSU=Polysubstance 
use NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001 
aComprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race 
bComprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”  




Table 3.4: Association between classes of polysubstance use and perceived barriers to accessing treatment 
for substance use disorder (NSDUH 2015-2017) (N=6,029) 
 Readiness Barrier Financial Barrier Structural Barrier Stigma-Related Barrier 
 aORa (95% CI) aORa (95% CI) aORa (95% CI) aORa (95% CI) 
Classes of PSU     
C1: Heroin injectors with 
high PSU 3.11 (1.43-6.77)
† 1.76 (0.64-4.85) 2.42 (1.22-4.79)* 3.13 (1.31-7.48)* 
C2: PPR users with low 
PSU Referent Referent Referent
 Referent 
C3: PPR users with high 
PSU 2.89 (1.41-5.93)
† 1.58 (0.75-3.33) 1.65 (0.83-3.26) 2.28 (0.99-5.24) 
95%CI=95% confidence interval, aOR=adjusted odds ratio, N=sample size, NSDUH=national survey on drug use and health, PPR=prescription pain reliever, 
PSU=polysubstance use, SUD=substance use disorder. 
aModel adjusted for age, sex, race/ethnicity, sexual identity, education level, total family income, urbanicity, insurance type, year, self-reported health, severe 
psychological distress, and average number of cigarettes/day. 


















Supplemental Table 3.1: Specific drugs making up substance use categories114  
 Classification Question for Misuse Drugs Included 
Hallucinogens  “How long has it been since you have used any hallucinogen?” 
LSD, also called 126 "acid"; PCP, also called "angel dust" or phencyclidine; peyote; 
mescaline; psilocybin, found in mushrooms; "Ecstasy" or "Molly," also known as MDMA; 
ketamine, also called "Special K" or "Super K"; DMT, also called imethyltryptamine, AMT, also called alpha-
methyltryptamine, or Foxy, also called 5-MeO-DIPT; Salvia divinorum; and any other hallucinogen besides 
the ones that have been listed. 
Inhalants  
“Have you ever inhaled any of the 
following substances, even once, for 
kicks or to get high?” 
amyl nitrite, "poppers," locker room odorizers, or "rush"; correction fluid, degreaser, or cleaning fluid; gasoline 
or lighter fluid; glue, shoe polish, or toluene; halothane, ether, or other anesthetics; lacquer thinner or other 
paint solvents; lighter gases, such as butane or propane; nitrous oxide or "whippets"; felt-tip pens, felt-tip 
markers, or magic markers; spray paints; computer keyboard cleaner, also known as air duster; some other 
aerosol spray; and any other inhalant besides the ones that have been listed. 
Pain Relievers  
“Have you ever, even once, used any 
prescription pain reliever in a way that 
a doctor did not direct the respondent 
to use it” 
Hydrocodone products (Vicodin®, Lortab®, Norco®, Zohydro® ER, or generic hydrocodone); 
Oxycodone products (OxyContin®, Percocet®, Percodan®, Roxicodone®, or generic oxycodone); Tramadol 
products (Ultram®, Ultram® ER, Ultracet®, generic tramadol, or generic extended-release tramadol); 
Codeine products (Tylenol® with codeine 3 or 4 or generic codeine pills); Morphine products (Avinza®, 
Kadian®, MS Contin®, generic morphine, or generic extended-release morphine); Fentanyl products 
Duragesic®, Fentora®, or generic fentanyl); Buprenorphine products (Suboxone®, generic buprenorphine, 
or generic buprenorphine plus naloxone); Oxymorphone products (Opana®, Opana® ER, generic 
oxymorphone, or generic extended-release oxymorphone), 148 Demerol®; Hydromorphone products 
(Dilaudid® or generic hydromorphone, or Exalgo® or generic extended-release hydromorphone); Methadone; 
Any other prescription pain reliever* 
Sedatives  
“Have you ever, even once, used any 
prescription sedatives in a way that a 
doctor did not direct the respondent to 
use it” 
Zolpidem products (Ambien®, Ambien® CR, generic zolpidem, or generic extended-release zolpidem); 
eszopiclone products (Lunesta® or generic eszopiclone); zaleplon products (Sonata® or generic zaleplon); 
benzodiazepine sedatives (flurazepam [also known as Dalmane®], temazepam products [Restoril®, or 
generic temazepam], or triazolam [Halcion® or generic triazolam]); barbiturates (Butisol®, Seconal®, or 
phenobarbital); or any other 
Prescription sedative.  
Stimulants  
“Have you ever, even once, used any 
prescription stimulants in a way that a 
doctor did not direct the respondent to 
use it” 
Amphetamine products (Adderall®, Adderall® XR, Dexedrine®, Vyvanse®, generic dextroamphetamine, 
generic amphetaminedextroamphetamine combinations, or generic extended-release amphetamine-
dextroamphetamine combinations); methylphenidate products (Ritalin®, Ritalin® LA, Concerta®, 
Daytrana®, Metadate CD, Metadate ER, Focalin, Focalin XR, generic methylphenidate, generic extended-
release methylphenidate, generic 
dexmethylphenidate, or generic extended-release dexmethylphenidate); anorectic (weight-loss) stimulants 
(Didrex®, benzphetamine, Tenuate®, diethylpropion, phendimetrazine, or phentermine); Provigil®; or any 
other prescription stimulant. 
Tranquilizers  
“Have you ever, even once, used any 
prescription tranquilizers in a way that 
a doctor did not direct the respondent 
to use it” 
benzodiazepine tranquilizers (including alprazolam products [Xanax®, Xanax® XR, generic alprazolam, or 
generic extendedrelease alprazolam]; lorazepam products [Ativan® or generic 
lorazepam]; clonazepam products [Klonopin® or generic clonazepam]; or diazepam products [Valium® or 
generic diazepam]); muscle relaxants (cyclobenzaprine [also known as 




Supplemental Table 3.2: Adjusted odds ratios for perceived barriers to accessing substance use disorder 
treatment in the past year by insured adults reporting past year opioid misuse (NSDUH 2015-2017)  
 Readiness Barrier Financial Barrier Structural Barrier Stigma-Related Barrier 
 aORa (95% CI) aORa (95% CI) aORa (95% CI) aORa (95% CI) 
Age      
18-25 years   Referent  Referent Referent Referent 
26-34 years 1.41 (0.74-2.69) 1.69 (0.79-3.62) 1.76 (0.95-3.26) 1.16 (0.53-2.54) 
35-49 years 1.49 (0.83-2.67) 1.22 (0.63-2.37) 1.16 (0.58-2.31) 1.08 (0.36-3.21) 
50-64 years 0.62 (0.22-1.72) 0.28 (0.03-2.86) 0.76 (0.21-2.73) 0.76 (0.11-4.99) 
Sex     
Male  0.89 (0.49-1.61) 0.87 (0.51-1.51) 0.75 (0.39-1.46) 0.74 (0.42-1.32) 
Female  Referent Referent Referent Referent 
Race/ethnicity     
Non-Hispanic White Referent Referent Referent Referent 
Non-Hispanic Black 0.44 (0.19-1.02) 0.96 (0.29-3.17) 1.01 (0.38-2.67) 0.53 (0.09-3.16) 
Hispanic 1.02 (0.47-2.21) 1.36 (0.39-4.71) 2.22 (0.95-5.17) 1.82 (0.59-5.57) 
Othera 1.00 (0.50-2.00) 0.24 (0.07-0.77)* 1.43 (0.50-4.08) 0.77 (0.27-2.22) 
Sexual identity     
Heterosexual Referent Referent Referent Referent 
Lesbian, gay, or bisexual 1.66 (0.99-2.80) 1.26 (0.62-2.54) 1.61 (0.84-3.06) 1.51 (0.71-3.21) 
Education level     
HS graduate or less Referent Referent Referent Referent 
Some college-graduate 1.36 (0.81-2.29) 1.03 (0.49-2.16) 1.02 (0.59-1.77) 1.55 (0.66-3.61) 
Total family income      
< $20,000 1.21 (0.70-2.11) 1.80 (0.81-3.98) 1.02 (0.53-1.97) 2.53 (1.27-5.03)† 
> $20,000  Referent Referent Referent Referent 
Urbanicity      
Large metro  Referent Referent Referent Referent 
Small metro  0.81 (0.44-1.51) 0.97 (0.55-1.70) 0.97(0.58-1.61) 1.90 (0.93-3.88) 
Non-metro  0.94 (0.51-1.74) 1.00 (0.48-2.09) 1.19 (0.60-2.36) 1.66 (0.61-4.50) 
Insurance type      
Private insurance Referent Referent Referent Referent 
Medicaid 3.47 (1.67-7.23)† 2.16 (0.80-5.84) 1.53 (0.61-3.83) 1.08 (0.38-3.10) 
Otherb 1.88 (1.06-3.34)* 1.15 (0.49-2.71) 1.85 (0.98-3.49) 0.55 (0.23-1.34) 
Survey year      
2015 Referent Referent Referent Referent 
2016 0.81 (0.42-1.55) 0.80 (0.41-1.59) 1.15 (0.60-2.21) 0.68 (0.25-1.82) 
2017 1.32 (0.72-2.42) 1.10 (0.56-2.17) 0.82 (0.44-1.52) 0.99 (0.52-1.86) 
Self-reported health     
Excellent/very good  Referent Referent Referent Referent 
Fair/poor 1.35 (0.74-2.45) 0.86 (0.48-1.53) 1.32 (0.85-2.07) 1.22 (0.52-2.88) 
Severe psychological distressc     
No < 13 Referent Referent Referent Referent 
Yes ≥ 13 3.48 (1.92-6.29)‡ 2.51 (1.15-5.48)* 2.90 (1.58-5.34)† 2.77 (1.44-5.34)† 
Average cigarette use per day 
for past 30 days  
   
Non-Smoker  Referent Referent Referent Referent 
<1-1 per day 1.51 (0.61-3.76) 1.53 (0.31-7.55) 2.77 (0.85-9.04) 0.73 (0.15-3.53) 
2-5 per day 2.45 (1.12-5.35)* 1.49 (0.34-6.48) 5.52 (1.90-16.03)‡ 3.59 (1.06-12.22)* 
6-15 per day 1.57 (0.70-3.53) 4.98 (2.21-11.23)‡ 4.93 (1.74-13.98)† 1.72 (0.53-5.51) 
16->35 per day 0.85 (0.35-2.02) 6.86 (3.07-15.36)† 5.74 (2.50-13.16)† 3.40 (1.27-9.15)* 
Classes of PSU     
C1: Heroin injectors with high 
PSU 3.11 (1.43-6.77)
† 1.76 (0.64-4.85) 2.42 (1.22-4.79)* 3.13 (1.31-7.48)* 
C2: PPR users with low PSU Referent Referent Referent Referent 
C3: PPR users with high PSU 2.89 (1.41-5.93)† 1.58 (0.75-3.33) 1.65 (0.83-3.26) 2.28 (0.99-5.24) 
%w=weighted percent, aOR=adjusted odds ratio, H+PPR=heroin and prescription pain reliever use, HS=high school, HO=heroin use only, IDU=injection drug use, N=sample size, 
NSDUH=national survey on drug use and health, PPR=prescription pain relievers use, SUD=substance use disorder. 
NOTE: Boldface indicates value of statistical significance; *α<.05, †α<.01, ‡α<.0001 
aComprised of Non-Hispanic native American or AK native, Non-Hispanic native HI or other Pacific Islander, and non-Hispanic more than one race 
bComprised of Medicare, CHAMPUS, Military Plans, and “any other health insurance not already listed”  




Table 4.1: Demographic and incident-related characteristics for nonfatal 
opioid overdoses in Chesterfield County and the Control County 2016-2020e 
(N=1,888)  






Age‡     
18-24 years   120 (11.9) 122 (13.9) 242 (12.8) 
25-34 years 385 (38.2) 264 (30.0) 649 (34.4) 
35-44 years 211 (20.9) 178 (20.3) 389 (20.6) 
45-54 years 151 (15.0) 161 (18.3) 312 (16.5) 
55-64 years 86 (8.5) 96 (10.9) 182 (9.6) 
≥ 65 years 56 (5.6) 58 (6.6) 114 (6.0) 
Sexd*    
Female 392 (38.9) 287 (33.1) 679 (36.2) 
Male  617 (61.2) 579 (66.9) 1196 (63.8) 
Race/ethnicityd‡    
Non-Hispanic White 740 (74.1) 554 (65.3) 1294 (70.0) 
Non-Hispanic Black 225 (22.5) 272 (32.1) 497 (29.9) 
Other  34 (3.4) 22 (2.6) 56 (3.0) 
Overdose year‡     
2016 224 (22.2) 191 (21.7) 415 (22.0) 
2017 244 (24.2) 223 (25.4) 467 (24.7) 
2018 244 (24.2) 214 (24.4) 458 (24.2) 
2019 275 (27.3) 231 (26.3) 506 (26.8) 
2020 22 (2.2) 20 (2.3) 42 (2.2) 
Overdose locationd†      
Private residence  684 (67.9) 521 (59.5) 1205 (64.0) 
Public area 308 (30.6) 322 (36.8) 630 (33.5) 
Residential facility  15 (1.5) 33 (3.8) 48 (2.5) 
Route of naloxone 
administrationd‡     
IV 285 (28.6) 483 (56.0) 768 (41.3) 
IN 602 (60.4) 243 (28.2) 845 (45.4) 
IM/ otherb 16 (1.6) 24 (2.8) 40 (2.2) 
Combinedc  94 (9.4) 113 (13.1) 207 (11.1) 
Total dose of naloxone    
0.4 – 0.99 mg 86 (8.6) 118 (13.9) 204 (11.1) 
1.0 – 1.9 mg 134 (13.5) 264 (31.1) 398 (21.6) 
2.0 – 2.9 mg 236 (23.7) 335 (39.5) 571 (31.0) 
3.0 – 4.9 mg 437 (43.9) 122 (14.4) 559 (30.3) 
≥ 5.0 mg 103 (10.3) 9 (1.1) 112 (6.1) 
%= percent, IM=intramuscular, IN=intranasal, IV=intravenous, mg=milligrams, N=sample size 
*α<.05, †α<.01, ‡α<.0001 
a All values reported as percentages within each column as N (%) 
b Other included all intra-muscular routes and any other routes of medication administration not already mentioned, 
including ET tubes, etc.  
c Combined is any individual who was administered naloxone through multiple routes  
dFrequencies may not add up due to missing values 





Table 4.2: Single interrupted time series of monthly nonfatal opioid overdoses in 
Chesterfield Countya (2016-2020) 
 P  Estimate  SE p-value  
Intercept  β0 2.877163 0.140802 <.0001 
Pre-Intervention Slope β1 0.013664 0.009478 0.1565 
Change in Level (pre-post interruption) β2 -0.326317 0.185637 0.0857 
Change in Slope (pre-post interruption) β3 0.001356 0.013343 0.9195 
Post-Intervention Slope  β1 + β3 0.01502 0.002959 --- 
SE=standard error, P=parameter 
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 – January 
31st 2020.  





Figure 4.1: Single interrupted time series analysis of nonfatal opioid overdoses in Chesterfield 
County 
Solid line= modeled trend for the monthly number of nonfatal opioid overdoses, dashed line = counterfactual, or predicted 
trend if no intervention had been implemented.  




Table 4.3: Multiple interrupted time series for monthly nonfatal opioid overdoses 
comparing Chesterfield County to Control Countya (2016-2020) 
 Parameter  Estimate  SE p-value  
Intercept  β0 2.851519 0.145439 <.0001 
Pre-Intervention slope (Control) β1 -0.003269 0.010277 0.7512 
Δ Level (pre-post interruption) (Control) β2 -0.148562 0.204838 0.4702 
Δ Slope (pre-post interruption) (Control) β3 0.024081 0.014280 0.0953 
Δ Pre-intervention level (Treatment vs. Control) β4 0.025645 0.198878 0.8977 
Δ Pre-intervention slope (Treatment vs. Control) β5 0.016933 0.013748 0.2214 
Δ Differences in level (pre-to-post intervention) 
(Treatment vs. Control) 
β6 -0.177755 0.271924 0.5150 
Δ Differences in slope (pre-to-post intervention) 
(Treatment vs. Control) 
β7 -0.022725 0.019214 0.2401 
 SE=standard error 
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 – January 31st 2020. 
aEstimates adjusted for overdispersion  
 
 
Figure 4.2: Multiple iteration time series analysis for Chesterfield County and the Control 
County  
Solid red line= modeled trend for the number of monthly nonfatal opioid overdoses for Chesterfield County, Solid blue line 
= modeled trend for the number of monthly nonfatal opioid overdoses in the control county 




Supplemental Table 4.1: Demographic and population characteristics for Chesterfield 
County and the Control County (2018) 
 Chesterfield Countya Control Countya 
Total population 348,556 329,261 
Age (years)   
19-24 years   91365 (26.2%) 76767 (23.3%) 
25-34 years 122578 (35.2%) 140009 (42.5%) 
35-44 years 137517 (39.5%) 131226 (39.9%) 
45-54 years 146533 (42.0%) 134387 (40.8%) 
55-64 years 137025 (39.3%) 127513 (38.7%) 
≥ 65 years 148957 (42.7%) 147537 (44.8%) 
Sex   
Male 168,039 (48.2%) 156,230 (47.4%) 
Female 180,517 (51.8%) 173,031 (52.6%) 
Race   
White 243,545 (69.9%) 192,633 (58.5%) 
Black or African American 88,221 (25.3%) 104,312 (31.7%) 
American Indian and Alaska 
Native 2,337 (1.0%) 1,356 (0.4%) 
Asian or Pacific Islander 14,453 (4.1%) 30,960 (9.4%) 





Supplemental Figure 4.1: Residual plot to assess for autocorrelation in the single 





Supplemental Figure 4.2: Estimates of autocorrelation for the single 
interrupted time series model of Chesterfield County 
ACF=autocorrelation function, resCF=residuals for Chesterfield 
Horizontal blue lines represent 95% confidence intervals 
 
Supplemental Table 4.2: Single interrupted time series of the monthly 
number of nonfatal opioid overdoses in Chesterfield County (not adjusted 
for overdispersion) 
 P  Estimate  SE p-value  
Intercept  β0 2.877163 0.095470 <.0001 
Pre-Intervention Slope β1 0.013664 0.006427 0.03350 
Change in Level (pre-post interruption) β2 -0.326317 0.125870 0.00953 
Change in Slope (pre-post interruption) β3 0.001356 0.009047 0.88084 
Post-Intervention Slope  β1 + β3 0.01502 0.0102873 0.15093 
SE=standard error, P=parameter 
NOTE: Pre-intervention = February 1st 2016 – January 31st 2018, Post-Intervention = February 1st 2018 – 
January 31st 2020. 
 
Supplemental Table 4.3: Multiple interrupted time series for the number of monthly 
nonfatal opioid overdoses comparing Chesterfield County to Control County (not 
adjusted for overdispersion) 
 P Estimate  SE p-value  
Intercept  β0 2.851519 0.102361 <.0001 
Pre-Intervention slope (Control) β1 -0.003269 0.007233 0.6513 
Δ Level (pre-post interruption) (Control) β2 -0.148562 0.144167 0.3028 
Δ Slope (pre-post interruption) (Control) β3 0.024081 0.010050 0.0166 
Δ Pre-intervention level (Treatment vs. Control) β4 0.025645 0.139972 0.8546 
Δ Pre-intervention slope (Treatment vs. Control) β5 0.016933 0.009676 0.0801 
Δ Differences in level (pre-to-post intervention) 
(Treatment vs. Control) 
β6 -0.177755 0.191383 0.3530 
Δ Differences in slope (pre-to-post intervention) 
(Treatment vs. Control) 
β7 -0.022725 0.013523 0.0929 
 SE=standard error, P=parameter 





Supplemental Figure 4.3: Residual plot to assess for 
autocorrelation in the multiple interrupted times series analysis 
of Control County and Chesterfield County 
 
 
Supplemental Figure 4.4: Estimates of autocorrelation for the 
multiple interrupted time series model for Chesterfield County 
and Control County  
ACF=autocorrelation function, MITSAres=residuals for multiple interrupted time series 
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